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The thesis is composed of four chapters: 
Chapter one comprises a general introduction providing 
an overview on malaria with emphasis in Preganancy 
associated malaria and including a description of 
human and murine placental structure, a detailed 
review on the existing PAM mouse models and a summary 
of TLR4 and IFNAR1 involvement in pregnancy and 
malaria. 
In chapter two presents the work published in 2012 
referring to the development of new PAM mouse models.  
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Chapter three includes a manuscript prepared for 
publication that dissects maternal and foetal 
contributions of TLR4 and IFNAR1 to PAM.  
Chapter four contains general conclusions and 
discussion on the work presented in this thesis. 
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Abstract 
Malaria is one of the most devastating diseases in the 
world. In Plasmodium endemic regions, pregnant women 
are among the most vulnerable groups. Pregnancy 
Associated Malaria (PAM) threatens both maternal and 
foetal lives. Despite differences between human and 
mouse placentas PAM mouse models recapitulate key 
pathological features of human PAM. Here we describe 
new PAM models of mid gestation infection in the 
C57BL/6 mouse. We demonstrated that infection with P. 
berghei variants NK65, K173 and the mutant ANKAΔpm4 
reproduce main PAM features such as: increased 
parasitaemia in pregnant females; elevated number of 
stillbirths; decreased foetal weight and placental 
pathology. The NK65 model was used to investigate the 
role of host factors, namely TLR4 and IFNAR1 in PAM 
outcomes. Making use of heterogenic pregnancies we 
dissected the contributions of maternal versus foetal 
TLR4 and IFNAR1 in poor pregnancy outcomes. We 
demonstrated that TLR4 expression in foetal placenta 
contributes to foetal viability in infected pregnant 
females. Accordingly, primary trophoblast cultures 
showed that foetal TLR4 contributes to the response 
against Plasmodium-infected erythrocytes. The same 
genetic mating strategy was used to reveal that 
maternal but not foetal IFNAR1 contributes to the 
pathogenesis of PAM namely, to increased levels of 
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maternal parasitaemia, higher percentage of abortions 
and low birth weight. 
Taken together, the generation of heterogenic 
pregnancies using this PAM model revealed a dual role 
of TLR4 and IFNAR1 inflammatory molecules in PAM, 
showing that maternal cells activation increases 
disease severity while placental cell responses 
confers foetal protection. This work provides an 
experimental system to dissect maternal from foetal 
components in the pathogenesis of PAM, which may poof 
useful for the molecular analysis of other pregnancy 
disturbances such as preeclampsia. 
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Sumário 
O Paludismo é uma das doenças mais devastadoras no 
mundo. Nas regiões onde o Plasmodium é endémico as 
grávidas estão entre os grupos mais vulneráveis à 
doença. O Paludismo Associado à Gravidez (PAM para 
Pregnancy Associated Malaria) ameaça tanto a vida da 
mãe como a do feto. Apesar das diferenças entre as 
placentas humana e de murganho, modelos de PAM em 
murganhos recapitulam as principais características 
patológicas de mulheres grávidas infetadas com 
Plasmodium. Neste trabalho é descrito um novo modelo 
de PAM onde murganhos da estirpe C57BL/6 são infetados 
a meio do período de gestação. É demonstrado que a 
infecção com as variantes NK65, K173 e o mutante 
ANKAΔpm4 do parasita P. berghei reproduzem as 
principais características de PAM, tais como: elevados 
níveis de parasitémia em fêmeas grávidas; elevado 
número de nados-mortos; redução no peso dos fetos e 
patologia da placenta. O modelo com a variante NK65 
foi posteriormente utilizado para investigar a 
contribuição de fatores inflamatórios, nomeadamente de 
TLR4 e IFNAR1, para a patogénese da doença durante a 
gravidez. Utilizando cruzamentos genéticos para gerar 
gravidezes heterogénicas foi dissecada a contribuição 
do TLR4 e IFNAR1 maternos vs fetais para a patologia. 
Demonstrou-se que a expressão de TLR4 na placenta 
fetal contribui para a viabilidade fetal em fêmeas 
grávidas infetadas. Em concordância com estes 
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resultados, demonstrou-se em culturas primárias de 
trofoblastos que a expressão de TLR4 contribui para a 
resposta contra eritrócitos infetados com Plasmodium. 
A mesma estratégia de acasalamento foi utilizada para 
revelar que o IFNAR1 materno, mas não o IFNAR1 fetal, 
contribui para a patogénese de PAM nomeadamente, para 
elevados níveis de parasitémia materna, elevada 
percentagem de abortos e reduzido peso dos fetos. 
Em suma, a geração de gravidezes heterogéneas 
utilizando este modelo de PAM revelou um efeito dual 
para as moléculas inflamatórias TLR4 e IFNAR1 em PAM, 
demonstrando que o estímulo através das células 
maternas aumenta a severidade da doença ao passo que 
as células placentárias fetais, quando estimuladas, 
conferem proteção ao feto. Este trabalho apresenta um 
modelo experimental que possibilita a dissecção do 
papel dos componentes fetal e materno para a 
patogénese da PAM podendo provar-se útil para a 
análise molecular de outras patologias que ocorrem 
durante a gravidez, como por exemplo a pré-eclampsia. 
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Chapter I  
- General Introduction 
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1.1 Malaria Overview 
Malaria is one of the most devastating diseases in the 
world particularly in tropical countries, accounting 
for roughly 216 million cases of Plasmodium spp. 
infection and 665.000 deaths from malaria in 2010 [1].  
In the late 19th century, the discovery of the malaria 
parasite and its mode of transmission, allowed the use 
of focal mosquito control and the wide availability of 
proper disease diagnosis and treatment led to virtual 
elimination of malaria in most northern countries in 
Western Europe. WHO launched the Global Malaria 
Eradication Programme in 1955, when effective 
elimination tools as DDT and chloroquine became widely 
available, for mosquito control and human blood stage 
parasite treatment. As a result, 37 previously endemic 
coutries were free of this disease by 1978, including 
27 in Europe and the Americas [2]. 
In other countries, as India and Sri Lanka, the burden 
of disease and deaths from malaria were greatly 
reduced. However, failure to sustain the programme led 
to a resurgence of malaria in many countries leading 
to increased parasite resistance to chloroquine and 
its replacements and mosquito resistance to DDT. The 
adoption of the Global Malaria Control Strategy, in 
1992 and in 1998, the Roll Back Malaria initiative,WHO 
instigated the resurgence of financial investment in
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Figure 1.1 - Malaria Endemic Regions and Countries according to WHO 
official World Malaria Report 2012 [3] 
malaria control, resulting in the adoption of 
artemisinin-based combination therapies for the 
treatment of malaria patients, the large scale 
deployment of insecticide-treated nets and, to a 
lesser extent, house spraying as mosquito control 
measures [2].Despite recent progresses, malaria is 
nowadays endemic in 99 countries worldwide, remaining 
an intractable problem in much of Africa.  
Malaria is a disease caused by Apicomplexan pathogens 
of the genus Plasmodium, of which Plasmodium 
falciparum is the most deadly. Plasmodium infection 
usually results in an uncomplicated, mild febrile 
disease in which intermittent episodes of fever and 
peaks of parasitemia are controlled by the host’s 
immune system and, eventually, eliminated. In some 
cases, however, the disease becomes severe and may 
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lead to death. Severe malaria, induced by Plasmodium 
falciparum in humans, encompasses serious 
complications including cerebral malaria, respiratory 
distress, metabolic acidosis and severe anemia.  
In malaria endemic regions, pregnant women and 
children under 5-years of age are the most vulnerable 
groups. It is estimated that nearly a quarter of all 
childhood deaths are caused by malaria and with over 
10,000 maternal deaths per annum mainly attributed to 
Plasmodium falciparum infection [4-7]. 
Malaria parasites are known for having a significant 
genetic and genomic plasticity [8], a characteristic 
that allows the parasite to evade the host immune 
system and favors the odds for the emergence of drug 
resistant strains. Although combination therapies with 
artemisinin derivatives are now highly effective, 
recent reports on emerging resistance to these 
compounds [9] call the urgency for new antimalarial 
drugs [6]. Likewise, vector research will be essential 
for the development of new insecticides as insecticide 
resistance is also becoming a major problem [10]. 
An effective malaria vaccine may ultimately complement 
available control strategies offering the most cost-
effective tool for disease prevention and eradication. 
In the recent years, considerable effort is being put 
towards vaccines aiming at significantly reducing 
Plasmodium falciparum induced morbidity and mortality 
[7]. One of the main global instigators/funders of 
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this research goal is the Melinda and Bill Gates 
Foundation that, in 2006 funded the Malaria Vaccine 
Technology Roadmap [11]. This action has established a 
global strategy with two important goals for malaria 
vaccine research: a vaccine that is 50% protective 
against severe disease and death by 2015, and a 
vaccine that prevents 80% of clinical malaria episodes 
by 2025.  
Such initiative notably boosted the progress in 
malaria vaccine in the last decade, with many 
different approaches being followed. One such research 
has dominated the advances for malaria vaccination; 
RTS,S – the first malaria vaccine candidate entering 
the phase 3 trials, involving 16,000 children in seven 
African countries [12, 13]. Preliminary data from this 
trial has shown to reduce clinical malaria episodes, 
and severe malaria episodes that carry a risk of 
death, by approximately 50% in groups of children aged 
5 to 17 months.  Even though protection waned within a 
few months, and the indications that, in younger 
children (6–12 weeks) vaccine efficacy is reduced to 
36.6% [12, 13], RTS,S continues on the path to 
licensure due to its anticipated ability to reduce 
severe morbidity in young children [7]. 
In face of such results, extra pressure is now in the 
hands of researchers developing new P. falciparum 
vaccines as they will need to show signifficantly 
higher protective efficacy than the 30–50% reported 
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for RTS,S. Furthermore, if malaria eradication is to 
be achieved, additional attention should be put in 
vaccine development efforts for species other than P. 
falciparum, especially Plasmodium vivax as other 
countries, such as India, are still facing high 
malaria endemicity [14]. 
Despite all the effort around the development of a 
malaria vaccine, this might unfortunately not be such 
an easy and hasty goal to achieve. Additionally, the 
parasites genetic variability and plasticity, together 
with mosquito’s ability to gain insecticide resistance 
require a constant need of immediate advances in drug 
and insecticide improvement.  
In this context, the growing body of molecular 
understanding on the host-parasite interactions 
responsible by disease severity presents as an 
important tool in the development of new and more 
effective therapies. 
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1.2 Parasite life cycle 
- general overview 
The Plasmodium spp. is a protist of the phylum 
Apicomplexa. These parasites need to cycle between an 
invertebrate vector (hematophagous insect e.g. the 
genus Anopheles, human vector) and a vertebrate host 
(mammals, birds or reptiles) in order to complete 
their life cycle that includes several development 
stages and, sexual and asexual, reproduction phases 
[15]. 
 
1.2.1 Plasmodium spp. developmental 
stages in the invertebrate vector 
The Plasmodium spp. life cycle in the mosquito begins 
when a female mosquito takes a blood meal from an 
infected vertebrate host carrying gametocyte parasite 
forms. Once in the mosquito, the ingested infected 
blood goes into the posterior midgut lumen, where male 
and female gametocytes initiate gametogenesis. This 
stage is induced by the decrease in temperature, 
increase in pH and exposure to mosquito derived 
xanthurenic acid [16, 17]. These stimuli induce 
activation of a calcium-dependent protein kinase in 
the male gametocyte (microagametocyte) leading to 
exflagelation. Exflagelation results in the 
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differentiation of each male gametocyte into eight 
haploid gametes, extremely motile due to axoneme 
assembly. Female gametocytes, or macrogametocytes, 
produce a single extracellular and non-motile 
spherical female gamete. 
Microgametes and macrogametes rapidly fertilize 
forming a diploid zygote. Fertilization is followed by 
endomeiotic replication, producing a single, 
approximately tetraploid zygote nucleus, assumed to 
contain four haploid meiotic products [18]. 
Soon after gamete fusion, the sessile zygote gradually 
matures into a motile, banana-shaped ookinete. At this 
stage, a day after the blood meal, trough gliding 
motility, parasites leave the posterior midgut lumen 
and penetrate the midgut epithelium. After traversing 
the midgut epithelium, the ookinete reaches the 
extracellular space between the midgut epithelium and 
the overlaying basal lamina. At this site begins its 
development into a sessile, spherical oocyst. During 
ookinete maturation, the parasite undergoes meiosis 
[18-20]. 
At the basal lamina, a thick extracellular capsule 
forms around the oocyst and all the molecular 
apparatus required for cell motility and invasion is 
reabsorbed. Subsequently, new basal lamina is 
synthesized beneath the developing oocyst, separating 
the parasite from the midgut epithelium. DNA 
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replication and protein synthesis machinery is now 
upregulated for a massive asexual parasite 
amplification - sporogony. Multiple nuclear divisions 
occur in each oocyst resulting in a multinucleated 
parasite that gradually grows in size. At the same 
time, the oocyst plasma membrane is folded inwards 
forming cervices across the cytoplasm, 
compartmentalizing it into individual sporoblasts. 
Subsequent sporozoite budding occurs, involving 
synchronized mobilization of nucleus and other 
cellular organelles into each budding sporozoite [18, 
20]. This culminates into the release of thousands of 
sporozoites into the hemocoel. 
The following migration of sporozoites into the 
salivary glands is still poorly understood. Some 
studies suggest this is a passive migration of the 
parasites, mediated solely by haemocoel circulation, 
while other studies suggest the role of a chemotaxis 
process [18, 20]. Recently, the sporozoite invasion-
associated protein 1 (SIAP-1) has been implicated in 
mediating efficient oocyst exit and migration to the 
salivary glands [21].   
Although found throughout the haemocoelic cavity, 
sporozoites accumulate in the toraxic salivary glands 
region, more specifically within the distal median and 
lateral lobes of the salivary gland. This precise 
localization suggests that there is specificity in the 
parasite/salivary glands interaction. 
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Figure 1.2 - Plasmodium sexual development in the invertebrate host. After a 
female mosquito takes a blood meal on an infected vertebrate host, ingested male 
and female parasite gametocytes fertilise and form the zygotes which in turn 
transform into motile ookinetes. Ookinetes traverse the midgut epithelium and, on 
the basal side of the epithelium, develop to the next parasite stage, the oocyst. 
Multiple nuclear divisions within each oocyst are followed by membrane 
partitioning and budding off of several thousand haploid sporozoites into the 
haemocoel. In the next step, sporozoites will reach and invade the median and 
distal lateral salivary gland lobes. Invasion of the salivary gland epithelial cells 
occur through the formation of a parasitophorous vacuole, following the 
interaction of sporozoites with the basal lamina. A second parasitophorous 
vacuole is formed around the sporozoites during their escape into the secretory 
cavity of the glands. Whenever the mosquito goes for a new blood meal, the 
parasites that have managed to escape this second vacuole and migrated into the 
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salivary ducts, will be ejected into a new vertebrate host where the asexual 
development will take place and the parasite life cycle completed (Figure 
reproduced under permission of authors [20]).  
After salivary gland cell invasion, the parasites 
remain in the cytoplasm only transiently. A second 
parasitophorous vacuole is thought to surround the 
sporozoites during their migration into the secretory 
cavity of the glands. The secretory-cell-derived 
vacuole then disintegrates, leaving an extracellular 
sporozoite free within the secretory cavity of the 
gland. Here, large numbers of sporozoites organize in 
bundles and remain viable throughout the mosquito 
life. At each feeding cycle, small numbers of these 
free sporozoites further migrate, by gliding motility, 
into the fine secretory ducts [18-20].  
When an infected female mosquito seeks for a blood 
meal, sporozoites present in the saliva are injected 
into the vertebrate host dermis, initiating the next 
phase of the parasite life cycle. 
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1.2.2 A simplified review of the 
Plasmodium spp. developmental 
stages in the vertebrate host 
Infection in the vertebrate host has two phases: an 
asymptomatic, short lived pre-erythrocytic stage and, 
an erythrocytic phase where iterative cycles of 
parasite replication in the host red blood cells take 
place causing malaria symptoms. 
Whenever one infected female mosquito goes for a blood 
meal, on average, approximately 100 sporozoites [22, 
23] present in the saliva of the biting female are 
deposited in the skin of the bitten vertebrate. In the 
skin, these forms undergo a significant increase in 
locomotion ability and trough gliding motility a 
proportion of these parasites traverses the host 
capillaries and enters the blood stream or lymphatic 
system. Once in the blood stream, sporozoites 
passively migrate to the liver.  
 
1.2.1.1 Plasmodium spp liver stage 
Interventions at the liver stage present, at the 
moment, the most promising intervention strategy as 
this phase precedes the symptomatic blood stage, is 
clinically silent and represents a bottleneck in the 
parasite life cycle. In the liver, sporozoites 
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actively traverse the sinusoidal barrier gaining 
access to hepatocytes. The liver sinusoid barier is 
composed of fenestrated endothelial cells and Kupffer 
cells (resident macrophages). This active traversing 
ability has been shown essential for successful 
hepatocyte invasion, as cell traversal mutant 
parasites have decreased in vivo infectivity, strongly 
suggesting that Kupffer cells are the main traversing 
routes [24, 25]. 
Once a sporozoite has traversed the sinusoidal 
barrier, it traverses several hepatocytes before the 
final host hepatocyte where it will replicate and 
differentiate [26, 27]. During hepatocyte invasion, 
the parasite is surrounded by a parasiphorous vacuole, 
the interface between parasite and host, within which 
it resides during liver stage development. This 
parasitophorous vacuole membrane, derived from the 
host, is further remodelled with parasitic proteins 
and lipids [28].Upon successful hepatocyte invasion 
and parasitophorous vacuole membrane formation, the 
sporozoite differentiates from an invasive form to a 
metabolically active, replicative form; the 
trophozoite.  
The sporozoite initiates its metamorphosis with the 
disruption of cytoskeleton beneath the plasma 
membrane, which harbours the invasion motor. This 
disruption results in a protruding, bulbous area 
around the nucleus. As this region expands, the two 
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distal ends of the sporozoite gradually retract, 
leading to parasite’s sphericalization. At the same 
time, a major intercellular rearrangement takes place 
with an active exocytic clearance of the organelles 
involved in invasion. At the completion of 
metamorphosis, only those organelles necessary for 
replication within the hepatocyte are retained [29]. 
Figure 1.3 - Schematic representation of parasite release from infected 
hepatocytes into the blood stream. After sporozoite, invasion of hepatocytes 
and repeated rounds of parasite nuclear division from a single nucleus to 
thousands of nuclei; breakdown of the parasitophorous vacuole membrane results 
in the release of thousands of detached daughter merozoites into the host cell. 
This figure depicts the release of Plasmodium merozoite-filled vesicles 
(merosomes, green) from infected hepatocytes into the blood stream. Red blood 
cells (red) are separated from hepatocytes by endothelial cells (orange); Kupffer 
cell is in blue. (Figure reproduced under permission of authors [30]) 
Once dedifferentiated, the trophozoite undergoes rapid 
growth, entering schizogony with numerous rounds of 
DNA and organelle replication. A multinucleated 
sincytium is thus formed within the infected 
hepatocyte. As a final step, the organelles undergo 
morphological and positional changes, before cell 
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division, finally segregating into individual 
merozoites [31]. 
Few to several thousand merozoites are packaged in 
vesicles, the merosomes [30]. Infected hepatocyte cell 
death is then induced causing the detachment from the 
surrounding tissue, followed by the budding of 
merosomes into the sinusoid lumen. At the same time, 
parasites inhibit the exposure of phosphatidylserine 
on the outer leaflet of the dying hepatocytes 
membranes and merosomes surface. This mechanism 
ensures hepatocyte-derived merosomes to evade 
detection and engulfment by Kupffer cells and 
guarantee safe delivery of merozoites into the 
bloodstream [30]. 
Merosomes then travel passively into the bloodstream 
through the heart and, eventually, into the narrow 
vasculature of the lung, where they burst and release 
merozoites into the bloodstream to initiate blood 
stage infection [32, 33]. 
 
 
 
 
 
 
18 
 
1.2.1.2 Plasmodium blood stage 
Malaria disease occurs during the asexual blood stage 
of infection, with host erythrocytes being invaded by  
merozoites. In approximately 48h, the 
intraerythrocytic parasite grows and divides into a 
schizont form containing daughter merozoites that are 
released into the blood stream perpetuating the 
invasion and replication cycle [34].  
Merozoites, deftly adapted to erythrocyte invasion, 
are the smallest form Plasmodium acquires during its 
lifecycle. Belonging to the Apicomplexa phylum, the 
merozoite has the conventional organelle repertoire of 
an invasive protozoan. This repertoire comprises an 
apical complex of three morphologically distinct 
secretory organelles - micronemes, rhoptries, and 
dense granules. These organelles are believed to be 
required in the process of adhesion (adhesins are 
released from micronemes) and posterior invasion 
(invasins) of the host cell. During invasion the 
organelle content is sequentially released with the 
final establishment of a parasitophorous vacuole 
(thought to be mediated by rhoptries) where the next 
rounds of replication/differentiation will take place. 
Mature merozoites are released from infected 
erythrocytes into the blood stream by rupturing the 
erythrocyte membrane, rapidly invading uninfected 
erythrocytes. 
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Figure 1.4 – Plasmodium life cycle in the human host. When going for a blood 
meal, an infected female mosquito injects a small number of infectious 
sporozoites into the human bloodstream while feeding. Shortly after, sporozoites 
are carried to the liver, where they invade and replicate inside hepatocytes. Later, 
thousands of daughter merozoites are released back into the bloodstream and 
enter erythrocytes being carried trough the organism within this cell type. As they 
mature inside erythrocytes, adhesion ligands are selectively expressed, enabling 
the maturing parasite to bind receptors expressed by endothelial cells that line the 
blood vessels in the deep vascular beds of organs such as the brain, lungs and 
placenta. After each maturation cycle, the parasitized erythrocytes rupture and 
release more daughter merozoites, thereby perpetuating and promoting the blood-
stage cycle. Some merozoites differentiate into gametocytes, which, when taken 
up by another feeding mosquito, perpetuate the sexual cycle in the insect. (Figure 
reproduced under permission of authors [35]) 
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The rapid process of de novo red blood cell binding 
and invasion with apical pole reorientation, involves 
multiple P. falciparum proteins.  
Once released from an infected erythrocyte (IE), 
merozoites are exposed to low potassium levels. This 
condition triggers calcium release activating the 
secretion of adhesins, one of the classes of proteins 
governing merozoite invasion functioning as ligands 
and binding directly to specific receptors on the 
erythrocyte surface. These proteins are located in 
both micronemes and rhoptries, and provide Plasmodium–
erythrocyte specificity. The main adhesins so far 
identified belong to two protein families that include 
the EBL and reticulocyte binding–like homologues 
(PfRh), localized, respectively, to the micronemes and 
neck of the rhoptries [36]. Initial interaction with 
erythrocytes involves dramatic movement of the 
merozoite, with parasite and hosts cell undergoing 
remarkable changes. The erythrocyte undergoes major 
surface deformation followed by an apparently active 
process of reorientation that places the parasite 
apical end adjacent to the host cell membrane. 
Commitment to invasion occurs once the merozoite’s 
apical end interacts with the erythrocyte, with the 
triggering of subsequent events leading to entry.  
Some proteins anchored to the merozoite plasma 
membrane via a glycosylphosphatidylinositol (GPI) 
anchor and others associated by interaction with 
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surface proteins have been suggested as main ligands 
in this initial step although irrefutable proof is 
still lacking. These proteins are not evenly 
distributed over the merozoite with some having apical 
concentrations, suggesting a direct role in invasion. 
Several proteins include domains suggesting their 
involvement in protein–protein interactions; as is the 
case for Duffy binding–like (DBL) or erythrocyte 
binding– like (EBL) domains that are specific to 
Plasmodium spp. and present in proteins expressed in 
phases as diverse as invasion, post-invasion 
remodeling and cytoadherence. Others include EGF and 
six-cysteine (6-Cys) domains, also implicated in 
protein–protein interactions. 
Invasins are also involved in merozoite invasion. 
These proteins function in the invasive process but do 
not necessarily bind directly to receptors on the host 
cell. Invasins appear to be essential for merozoite 
invasion being the apical membrane antigen-1 (AMA1) 
the best characterized of these proteins. AMA1 
interacts with a set of rhoptry neck proteins (the RON 
complex) that comes together at the tight junction 
during invasion [36]. 
At this stage, the apical membrane antigen 1 (AMA1) 
moves to the merozoite surface and binds a segment of 
rhoptry neck protein 2 (RON2). The RON proteins are 
secreted into the erythrocyte membrane while a segment 
of RON2 remains outside the erythrocyte membrane to 
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bind AMA1. RON2 functions as an anchor in the 
erythrocyte membrane for RON complex assembly, and as 
a possible grip that the merozoite uses for invasion.  
Formation of the erythrocyte-parasite junction likely 
triggers the release of the rhoptry bulb, providing 
proteins and lipids required for the parasitophorous 
vacuole and its membrane to establish the space into 
which the merozoite can move as it invades.  
Actin filaments also concentrate at this site, 
presenting a ring like distribution at the tight 
junction, trailing the RON complex. This likely 
provides a substrate with which the actin-myosin motor 
propels the merozoite into the space generated by 
release of the rhoptries bringing the merozoite into 
the erythrocyte. As the parasite moves into the 
erythrocyte, the tight junction is pulled across the 
surface of the merozoite, drawing with it the 
erythrocyte membrane until the resealing of the 
parasitophorous vacuole and the erythrocyte membrane 
[36].  
Now, the internalized parasite is presented in a ring-
loke form, undergoes rapid and dramatic 
transformation/maturation [6, 34, 36-39].  
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After the differentiation/maturation period, the 
parasitized/infected erythrocytes (IE) rupture and 
release more daughter merozoites, thereby feeding and 
amplifying the blood-stage cycle. It is during this 
intra-erythrocytic proliferative period that the 
maturation into male and female gametocytes might take 
place, by commitment to the sexual pathway [40].  
Figure 1.5 - Simplified representation of a Plasmodium falciparum merozoite 
invading an erythrocyte. Depicted is the complex process of invasion with a 
general overview of the multiple receptor–ligand interactions between the 
erythrocyte and components of the parasite surface and respective apical 
secretory organelles. (Figure reproduced under permission of authors [38]) 
The uptake of these sexual forms during the blood meal 
of a female mosquito completes the parasite’s life 
cycle. 
It is during this blood stage of perpetuated invasion 
and release of merozoites to and from erythrocytes, 
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with rapid multiplication, that severe forms of 
malaria take place with pregnant women and children 
being the higher risk groups. Corresponding symptoms 
as fever, anaemia, respiratory distress, lactic 
acidosis and in some cases coma and death [41, 42] are 
generally attributed to P. falciparum infections, 
although P. vivax infections also have an often 
neglected contribution to the worldwide disease burden 
[43-45]. 
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1.3 Human Pregnancy Associated 
Malaria 
Pregnant women are at greater risk of malaria 
infection and symptomatic disease than the same women 
before pregnancy or non-infected adult controls [46, 
47]. P. falciparum and/or P. vivax [48-50] infections 
during pregnancy are a major public health problem, 
with substantial risks for the mother, foetus and the 
newborn. In the mother, this form of disease 
encompasses a large spectrum of clinical 
manifestations ranging from mild to severe anaemia, 
pulmonary oedema, cerebral malaria or renal failure 
and is associated to spontaneous miscarriage, 
stillbirth, preterm delivery and foetal growth 
retardation [51, 52].  
To face this health problem, the World Health 
Organization has recommended a package of malaria 
control interventions  which includes promoting usage 
of insecticide-treated nets, intermittent preventive 
treatment with sulfadoxine-pyrimethamine during 
pregnancy and appropriate case management through 
prompt and effective anti-malaria treatment of 
pregnant women [53].  
Severity of malaria in pregnancy is dependent of many 
factors including the number of previous pregnancies 
and local malaria endemicity. Pregnancy Associated 
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Malaria (PAM) is usually more severe in areas of low 
endemicity where immunity to infection has not been 
previously acquired [54, 55]. In these low endemicity 
conditions, primigravidade or multigravidae do not 
significantly differ in PAM susceptibility and the 
severity of disease is a matter of extreme concern 
[55, 56]. In contrast, in high endemicity areas, less 
severe manifestations of PAM usually occur. In these 
regions women had acquired some degree of protection 
to infection and the effects of PAM in both mother and 
foetus are less severe [57-59]. These distinct 
epidemiological features result in contrasting 
consequences of malaria during pregnancy [60]. 
PAM severity is also dependent on parity. In areas of 
unstable malaria transmission, primigravidae are more 
susceptible to disease [61]. Intermediate outcomes 
have been registered in meso-endemic regions where 
secondigravidae present outcomes similar to those of 
primigravidae in endemic regions [48]. 
Different hypotheses have been presented as to why 
pregnant women present higher susceptibility to 
infection. It has been hypothesized that the immuno-
suppressed state due to the pregnancy status would 
counteract a proper humoral response to the parasite; 
nevertheless no consensus has been reached as to 
determining which immunological components are 
involved in conferring higher susceptibility to 
malaria during pregnancy [59]. An alternative non-
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exclusive explanation is the ability of P. falciparum 
to selectively adhere to the placental tissue. 
Pregnancy associated malaria often entails marked 
accumulation of IE in the intervillous space of the 
placenta, possibly leading to maternal anaemia, low 
birthweight, prematurity and increased infant 
mortality [62].   
Accumulation of P. falciparum infected erythrocytes 
(IE) in microvasculature endothelium in different 
organs is believed to be a key factor in malaria 
associated pathology. This ability is mediated through 
the insertion, in the IE membrane, of parasite-
encoded, clonally-distributed variant surface antigens 
(VSA). IE sequestration is perceived as an immune 
evasion strategy to avoid splenic clearance of 
infected erythrocytes [63-66]. Antigenic variants are 
coded by the var gene family that enables the 
expression of a large repertoire of P. falciparum 
erythrocyte membrane protein 1 (PfEMPl) variants[67, 
68] that mediate adherence to endothelial cells [69]. 
Endothelial cell receptors such as CD36, 
thrombospondin (TSP), and intercellular adhesion 
molecule 1 (ICAM-1) have been identified as major host 
receptors for mature IE and to be directly involved in 
the severe malaria forms, as is the case of cerebral 
malaria [70-75]. 
The ability of the proteoglycan chondroitin sulphate A 
(CSA) to mediate IE adhesion was first described in 
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vitro [76, 77] and demonstrated to be the main 
mechanism of specific adhesion to placenta [66, 78]. 
It was thus evident that the placenta would constitute 
a specific and differential niche for an antigenically 
distinct VSA. This single, uniquely structured var 
gene was first identified in 2003; the NFAvar2csa gene 
[63]. NFAvar2csa is transcribed at higher levels from 
placental parasite isolates than from peripheral blood 
isolates of non-pregnant malaria patients [65]. With a 
particularly unique structure, it is the only var gene 
that does not have an N-terminal DBL-α domain and, as 
in only three other var genes, it lacks a CIDR domain 
and it does not contain a DBL-γ domain, like eight 
other 3D7 var genes [64]. 
As to why do P. falciparum variants are specifically 
selected during pregnancy was clarified in 2000 by 
Achur, R.N. and colleagues [66]. In this study, the 
chondroitin sulfate proteoglycans (CSPGs) of human 
placenta were purified, structurally characterized, 
and the adherence of IE to these CSPGs accessed. Three 
distinct types of CSPGs were identified. Nevertheless 
significant quantities of an extracellular low 
sulphated form uniquely found in the placenta 
intervillous spaces, was identified as the most 
efficient in binding IEs [66].  
Taken together, the specific presence of CSPG low 
sulphated form in the placenta, might be the reason 
why primigravidae are less able mounting an efficient 
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immune response to the specific cytoadherent forms of 
the parasite developed during pregnancy, even if they 
were infected prior pregnancy. This also points to why 
multigravidae present increased protection to PAM; 
being previously exposed to the Var2CSA variant 
renders them with specific IgG antibody levels which 
have been suggested directly relate to the protective 
immune response multigravidae present [79].  
These observations provide an alternative explanation 
to the epidemiology of maternal malaria in spite of 
the changes in the cellular immune system during 
pregnancy.  
In sum, in the search for understanding causes and 
consequences of increased severity of Plasmodium 
infection during pregnancy, both maternal 
physiological changes occurring during pregnancy and 
the parasite variation/adaptation characteristics 
should be taken into account as they may have a 
synergistic effect in increasing susceptibility to 
infection. 
Additionally, recent reports have pointed for an 
active role for the foetal placental tissue in IE 
uptake upon binding to trophoblasts [76]. These new 
observations raise the hypothesis that there might be 
a third, so far unaddressed, player in PAM outcome – 
the foetus. 
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One of the main subjects of the work present in this 
thesis is the putative role of this “third player” 
during PAM.  
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1.4 Placentae 
The word placenta originates from the Latin flat cake, 
from Greek plakóenta, accusative of plakóeis, from 
plak-plax "flat surface" [80].  
By deffinition, placenta is "the vascular organ in 
mammals except monotremes and marsupials that unites 
the fetus to the maternal uterus and mediates its 
metabolic exchanges through a more or less intimate 
association of uterine mucosal with chorionic and 
usually allantoic tissues" [80]. 
 
1.4.1 Human and murine Placentae 
- General development and structure 
Uterine decidualization, characterized by the 
transformation of uterine stromal cells into large 
decidual cells with a secretory phenotype, and the 
recruitment of specialized macrophages and granulated 
lymphocytes, have a different timings and triggering 
mechanisms in humans and mice. While in humans the 
first signs of decidualization are seen before 
conception, as early as day 23 of the normal menstrual 
cycle, in mice, decidualization is only induced upon 
embryo implantation. 
In humans, as early as day 21 of pregnancy, the 
chorionic villus – definitive functional and 
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structural unit of the placenta – is already 
established. Subsequent to blastocist adhesion, 
trophoblasts rapidly start to proliferate, undergoing 
posterior fusion, in order to form the multinucleated 
syncytiotrophoblast, which invades the maternal 
uterine stroma [81].  
The haemotrophic function of the definitive placenta 
is considered established when all the factors 
required for physiological exchange between maternal 
and fetal blood circulations are present. In humans, 
an effective arterial circulation is completely 
established around the 12
th
 week of gestation, during 
which period the human embryo has largely completed 
the organogenesis stage. 
Distinct from the human placenta, the mouse placenta 
only achieves its definitive structure halfway through 
gestation. Importantly, murine placentation evolves 
from an initially choriovitelline pattern to a 
chorioallantoic pattern at 11.5 days. Specifically, 
maternal blood is evident in the labyrinth at E10.5, 
but not at E9.5. Extensive fetal capillary formation 
is seen by E12.5, but not at E10.5 [81]. 
By 12.5 days of gestation, the murine definitive 
chorioallantoic placenta is finally developed [81, 
82]. This is reflected in a late trophoblastic 
invasion leading to a distinct timing on the point at 
which fetal direct nutrient uptake from circulating 
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maternal blood by trophoblast cell, when in comparison 
to human placentas.  
Despite the differences in placental development 
between mice and humans, some similarities can be 
found between the two species. For example, the 
trophoblast cell lineage seems to follow the same 
pathways: an invasive pathway involving extravillous 
trophoblasts in humans and giant cells and 
trophoblastic glycogen cells in mice; and an exchange 
barrier involving the syncytiotrophoblast in both 
species. Furthermore, also at molecular level, the 
expression of certain placental genes has been  
described for both human and mouse [81]. 
 
1.4.2 Placental structure in human and 
mice 
1.4.2.1 The human Fetal placenta and the murine 
Labyrinth 
The human fetal placenta is functionally analogous to 
the murine labyrinth as, in both, fetal and maternal 
blood circulates in close association for 
physiological exchange. In both species, the foetal 
interface is represented by a layer of trophoblasts 
supported by an extracellular matrix, collectively 
known as the chorionic plate. The umbilical cord is 
inserted at the center of the fetal chorionic plate 
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where the fetal arteries and veins, derived from the 
allantoic mesenchyme, ramify. These umbilical vessels 
irradiate to and from the foetus, connecting it to the 
placenta, allowing fetal blood circulation in the 
placenta.  
From the opposite surface of the chorionic plate arise 
many tree-like projections known as chorionic villi. 
The outer-most layer of the chorionic villi is 
trophoblastic whilst its inner core consists of 
allantoic mesenchyme and vasculature, continuous with 
that of the umbilical cord. The allantoic vasculature 
and its associated blood circulatory system within the 
fetus itself constitute the feto-placental 
circulation. The trophoblastic layer of the chorionic 
villi is directly bathed in maternal blood which is 
brought to and leaves the fetal placenta/labyrinth via 
the arterial and venous sinuses from the basal 
plate/junctional zone and the adjacent uterine tissue, 
known as the utero-placental circulation.  
Based on the overall shape of this region, both 
species are considered discoid because their placentae 
resemble a circular cake with a flat surface facing 
the fetus and an irregular oposite surface adjacent to 
the uterine wall. The basic architecture similarities 
between the human fetal placenta and the murine 
labyrinth classifies them both as chorio-allantoic 
since the tissue separating circulating maternal from 
fetal blood consists of chorionic trophoblast and 
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allantoic mesenchyme and vasculature. Additionally, 
they both have a haemochorial interface as feto-
maternal interactions between the two blood 
circulations involve direct interaction between 
maternal blood and chorionic trophoblast. 
However, regarding the chorionic architecture, human 
and mice placentae are differently categorized. Due to 
their tree-like pattern with innumerable branches the 
humans are considered to have a villous placenta, 
while in mice, the interconnected branches of the 
chorionic projections generate a maze-like pattern, 
the so called labyrinthine placentae.  
The space within which maternal blood circulates in 
the human fetal placenta is more open and termed as 
the intervillous space; in mice, this space is named 
as maternal blood spaces or lacunae. As a result of 
these differences, the mouse labyrinthine structure 
allows countercurrent exchanges between maternal and 
fetal capillaries arranged in parallel to each other. 
In humans, the multivillous structure, considered to 
be less efficient, is intermediate between a 
countercurrent and a parallel-flow [81]. 
The physiologically important exchange of substances 
between fetal and maternal blood takes place through 
foetal-derived cells at the feto-maternal interfaces. 
In humans, these are the villous trophoblasts. Villous 
trophoblasts, remain attached to the villous basement 
membrane, forming a monolayer of epithelial cells. 
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These cells proliferate and differentiate, to form a 
syncytiotrophoblast that covers the entire surface of 
the villus. The syncythiotrophoblast is 
multifunctional, but its primary functions are 
absorption, exchanges and specific hormonal functions.  
The surface of the villous syncytiotrophoblast has 
numerous microvilli. They are believed to increase the 
surface area and create areas of relative stasis of 
maternal blood plasma, thus allowing more time for 
absorption. In mice, in contrast to the single layered 
syncytiotrophoblast in humans, the trophoblastic 
interface is considered to have three layers: two 
syncytiotrophoblast layers in contact with the fetal 
endothelium, and one cytotrophoblast layer in contact 
with maternal blood. This type of placental 
development is known as haemotrichorial placentation 
while the human placentation is monochorial. The 
murine trophoblast layer lining the maternal blood 
spaces (1
st
 layer), is not a syncytium as in humans, 
but consists of discontinuous layer of trophoblast 
cells (cytotrophoblast) that do not show microvilli. 
The middle and third layers (2
nd
 and 3
rd
 layers 
respectively) are syncytiotrophoblastic. The maternal 
surface of the middle layer is loosely attached to the 
1
st
 layer and contains irregular invaginations 
generating spaces between it and the adjacent 1
st
 
layer. Importantly, the 1
st
 layer is not the only 
trophoblast layer that directly contacts with the 
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maternal blood spaces but also the 
syncytiotrophoblast, on the 2
nd
 layer.  
The anatomy of the rest of the labyrinthine interface 
is very similar to the human foetal placenta.  
Figure 1.6 – Schematic representation of the main regions and cell types of 
human and murine placentae at the last third of gestation. At the top half is 
depicted the maternal side while the bottom half represents the foetal counterpart. 
Arrows indicate the direction of maternal blood flow. The following constituents 
are represented in the picture: bp- basal plate, mv- maternal veins, zi- zona intima, 
l- murine labyrinth, cpp- chorionic plate projections, jz- junctional zone, cma- 
murine central maternal artery, avb- anchoring villous branch; avm- allantoic 
vasculature and mesenchyme, bp- basal plate, bpet- basal plate endovascular 
trophoblast, bpit- basal plate interstitial trophoblast, bpvc- basal plate venous 
channel, cc- cytotrophoblastic cell column, cma- central maternal artery, cp- 
chorionic plate, cpp- chorionic plate projection, db- decidua basalis, fp- fetal 
placenta, igc- invading glycogen trophoblast cells, ivs- intervillous space, jz- 
junctional zone, jzgc- junctional zone glycogen trophoblast cells, jzst- junctional 
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zone spongiotrophoblasts, jzvc- junctional zone venous channel, l- labyrinth, m- 
myometrium, mbs- maternal blood spaces, msa- maternal spiral arteries, mv- 
maternal veins, pbit- placental bed interstitial invasive trophoblast, pbet- placental 
bed endovascular trophoblast, tgc- trophoblast giant cell, tgcz- trophoblast giant 
cell zone, tv- terminal villi, uc- umbilical cord, vt- villous tree and zi- zona intima. 
(Figure reproduced under permission of authors [82]) 
Thus, analogous cell types among human and murine 
trophoblasts have been identified, including 
proliferative trophoblastic cells and cells 
differentiating into syncytium. In both humans and 
mice, placentation involves the development of three 
physiologically and anatomically distinct regions: the 
human “fetal placenta” or murine labyrinth; the basal 
plate or junctional zone, for humans and mice, 
respectively and; the maternal uterine tissue 
bordering the maternal side of the murine trophoblast 
giant cell zone or the human basal plate [81, 82]. 
Furthermore, additional cell types that are neither 
trophoblasts nor vascular endothelial cells are found 
in some areas of the villous core and in the mouse 
placenta labyrinth and include pericytes and 
macrophages or so-called Hofbauer cells [81, 82]. 
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In conclusion, despite important morphological 
differences between the human and murine placentas 
there are similarities in the general placenta 
architecture and comparable physiological roles at the 
cellular level that allow using the mouse as a model 
to study cellular and molecular mechanisms impacting 
on the placental barrier physiology.  
Figure 1.7 –.General comparison of mouse and human pacentation and 
gestation events and timing (Table reproduced under permission of author 
[83]) 
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1.5 Mouse models 
A variety of mouse models of PAM have been established 
that are instrumental in the investigation of PAM 
pathogenesis. While acknowledging differences between 
human and mouse placenta these models take advantage 
of functional similarities between human and mouse 
placentas namely in respect to the nature of 
interhemal barrier. PAM mouse models mainly focus on 
conditions that best fit low endemicity scenarios 
where acquired immunity to infection is very low or 
absent and PAM is severe. Nevertheless, the current 
mouse models offer a generous variety of infection 
conditions that range from infection prior to 
pregnancy to infection early or late in the gestation 
period, covering different parasite species and mouse 
strains.  
 
1.5.1 Infection prior gestation 
Infection prior gestation has generated mouse models 
to study parasite recrudescence during pregnancy. The 
first recrudescence model was established in 1980 by 
Adriaan A.J.C. van Zon and Winjnand M.C. Eling 
[84]with the aim to study “recrudescence as a marker 
for depressed immunity in pregnancy”. The 
recrudescence model arose using the rodent parasite P. 
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berghei K173 in the Swiss, C3H/StZ and B10Lp mouse 
strains. 
This model consists on infecting virgin naïve females 
and consecutively treating them with sulfadiazine for 
31 days, in order to clear parasitaemia. Two days 
after the treatment is stopped, females are challenged 
with a new injection of IE in order to confirm 
acquired immunity. Upon this challenge, only 
subclinical numbers of persisting parasites were 
observed with rare spontaneous recrudescence. However, 
in subsequent pregnancy, 40 to 49% of recrudescence 
cases were observed (depending on the strain). This 
model of P. berghei K173 recrudescence also revealed 
malaria-associated prematurity, abortion and death 
before parturition in 20% of recrudescent pregnant 
females. Despite the high rate of death in 
recrudescent females, it was possible to register 
reduction in the incidence of recrudescence in 
multigravidae, corresponding to the observations made 
in pregnant women.  
Overall, the P. berghei K173 recrudescence mouse 
model, revealed to be an excellent experimental new 
tool for the analysis of the mechanism of “depressed 
malarial immunity” during pregnancy, as it exhibits 
several similarities with the human disease allowing 
for manipulation and experimental control that is not 
amenable when studying human PAM. 
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Nevertheless, the fact that a high proportion of the 
mice that recrudesced during their first pregnancy 
died from the infection impeded as the study of PAM in 
multigravidae.   
This drawback led those authors to address the 
question from a different angle and test whether the 
depression in the immune response would be different 
from the first to subsequent pregnancies. A very 
interesting finding was made using this alternative 
approach. Briefly, a group of immune Swiss mice (prone 
to recrudescence) was treated with chloroquine before 
mating and supplemented with chloroquine in drinking 
water for the duration of the first pregnancy. After 
parturition the mice were reinfected and allowed to 
mate again. During the second pregnancy 46% (11 mice) 
exhibited recrudescence, the same percentage as 
observed in primigravidae. With this result it was 
shown that fundamental differences in the 
immunological capacity of the host between the first 
and a subsequent pregnancy, is unlikely. The authors 
suggested that the presence of the parasite during 
pregnancy strengthens immunity that would thereby 
prevent loss of immunity in a subsequent pregnancy.  
In a subsequent publication, Adriaan A.J.C. van Zon et 
al. [85] questioned further how the recrudescent 
mechanism would act during pregnancy and whether a 
lower recrudescence rate in multigravidae is the 
consequence of stronger immunity, how this is 
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achieved, and what was the role of the parasite as 
antigenic signal for development of this better 
immunity. Starting from the observation that mice 
protected from lethal recrudescence during their first 
pregnancy usually do not exhibit recrudescence in 
subsequent pregnancies [86], van Zon and colleagues 
hypothesized that an enhanced parasite load during the 
first pregnancy would be necessary to strengthen 
immunity. 
Their first approach was to test if repeated 
challenges before pregnancy would strengthen immunity 
and consequently prevent loss of immunity during the 
first pregnancy. A group of female mice was infected 
eight times and allowed to mate after the last 
injection and recrudescence rates were recorded. 
Obtaining rates of recrudescence in the order of 40%, 
the authors inferred that prior-gestation challenge 
would not improve protection to recrudescence during 
pregnancy. The next step was to verify if improved 
immunity in subsequent pregnancies was due to enhanced 
ability to clear parasites (switch from premunity to 
sterile immunity). To address this, groups of mice 
were challenged within 1 week after parturition and 
parasite clearance accessed 2 weeks post challenge. 
With this experiment, the authors could observe that, 
in comparison to immune virgin mice, with a clearance 
rate of 10%, females that presented parasitaemia 
during a previous pregnancy had now a clearance rate 
of 82%. On the other hand, if no parasite was detected 
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during a previous pregnancy the clearance did not 
improve in comparison to immune virgin mice. These 
results led to the conclusion that the enhanced 
clearance observed in recrudescent females requires 
active infection during the first pregnancy. 
Furthermore, the authors show that not only the 
presence of proliferating parasites is required during 
pregnancy but also that it is essential in the second 
half of the gestation period to enable pos-gestation 
parasite clearance. Interestingly, a further 
experiment showed that the immunity acquired during 
pregnancy minimizes the loss of immunity when compared 
with virgin mice [86].  
Whether immunization prior pregnancy confers 
protection to infection during pregnancy was further 
accessed in lethal P. yoelii infections of ICR 
pregnant mice. In this study, females were 
hyperimunized with irradiated parasite and 
subsequently set to mate. When challenged on 
gestational day 14, these pre-immunized pregnants were 
able to control parasitaemia to a sub-patent level, 
with no impact on pregnancy outcome or maternal 
survival [87]. Of major importance, in this study, the 
authors show that even in the presence of relevant 
levels of peripheral blood parasitaemia, close to 40% 
IE, no parasite passes through the placental barrier 
to the foetus. When in the presence of IE, in vitro, 
isolated trophoblasts and placental macrophages, 
presented the same phagocytic activity as peritoneal 
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macrophages [87]. Although not directly related with 
recrudescence or the outcome of different gestational 
times of infection, this observation offers an 
important clue to why are IEs and parasites not 
detected in the foetal compartment. 
Eighteen years passed before the recrudescence theme 
was again addressed with two independent studies 
adding more detailed information on this subject. 
In one of these studies, infection of non-pregnant 
Balb/c females with the K173 strain of the P. berghei 
parasite, followed by sulfadiazine treatment, resulted 
in subpatent parasitaemias after posterior challenge 
[88]. Upon mating, 100% of the pre-exposed 
primigravidae, presented parasite recrudescence 
leading to intrauterine growth retardation and smaller 
litter sizes. In accordance with the previous studies, 
decreased levels of parasitaemia were observed in 
subsequent pregnancies, correlating with reduction in 
maternal anemia. As for P. falciparum [66], these 
authors questioned whether the susceptibility to 
pregnancy-related recrudescence, in mice, could be due 
to the parasite expression of pregnancy-specific VSAs. 
Based on an established flow cytometry analysis [89], 
where IgG levels specific for antigens on IE obtained 
during pregnancy-related recrudescence are evaluated, 
they showed that IE from pregnant and non-pregnant 
mice are partially different. After immunization, 
virgin females did not present IgG specific for 
47 
 
antigens specific of IE obtained during recrudescence 
but, recrudescence-specific IgG was posteriorly 
acquired over the course of several pregnancies and 
recrudescences [88]. With these observations the 
authors concluded for a modulator effect of IgG with 
specificity for recrudescent IEs VSAs on pregnancy-
related recrudescence. This study continues with a 
more detailed analysis on placental IEs. Their 
analysis shows that there is a preferential 
accumulation of IE mature stages when compared to 
peripheral blood IE, where ring-stage parasites are 
predominant [88]. 
A more detailed scrutiny on placental sequestration 
and pathology was published, in the same year, by 
Marinho and colleagues. In this elegant study, using 
Balb/c females and the P. berghei ANKA parasite, the 
authors demonstrate that the percentage of 
recrudescent females, and the associated parasitaemia, 
significantly decrease with increased parity [90]. As 
general observation, also in this study a poor 
pregnancy outcome is observed, characterized by 
decreased foetal viability and intrauterine growth 
retardation. Regarding placental pathology, a positive 
correlation was observed between peripheral 
parasitaemia and reduction in the vascular spaces. 
Furthermore, quantification of cell-type specific mRNA 
expression revealed increased amounts of inflammatory 
cells as NK, T cells and macrophages, in placentas 
from recrudescent females. This increase in 
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inflammatory cells was accompanied by a significant 
increase in the expression of macrophage 
chemoatractants MCP-1 and MIP1-α. Expression of 
vascular stress related molecules, HO-1 and ET-1, were 
also significantly increased in recrudescent 
placentas.  
As mentioned in the previous study and in human PAM, 
IE specific sequestration in placenta might be a 
pathogenic trigger for placental pathology. In this 
study, IE from non-pregnant males and females were 
compared to IE from recrudescent females on their 
ability for placental adhesion. Strikingly, IE from 
recrudescent females presented a four-fold increase in 
adhesion to placental sections. This adhesion was 
partially inhibited in the presence of chondroitinase 
or CSA suggesting the involvement of these molecules 
in adhesion and that parasites expanded during 
recrudescence display an enhanced specificity to 
placenta [90]. 
Amongst the recrudescence models we can find those 
displaying pathological features resembling human PAM 
in high to mid endemicity regions [84, 85, 87] and 
others of low endemicity [88, 90].  
Overall, recrudescence models are a valuable tool to 
evaluate acquisition of immunity prior pregnancy and 
malaria immunity disturbances during pregnancy. 
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1.5.2 Infection in early pregnancy 
Mouse models of infection at the initial stages of 
gestation allow studying the development of maternal 
antimalarial immune responses and its impact on 
malarial infection in early pregnancy prior and during 
placentation. 
Poovassery J. and Moore J.M. [91]established a model 
on the C57BL/6 background using the P. chabaudi AS 
parasite (1x10
3
 IE) to infect pregnant females at G0. 
They observed that pregnant females infected were able 
to recover from infection with no major differences in 
peripheral parasite levels when compared with non-
pregnant females. Pregnancy was unsuccessful in all 
cases, although most pregnant mice recovered from 
infection. A time-course analysis of the pregnant 
uterus revealed non-viable fetuses and resorptions 
scars from G12 onwards. This correlated with 
accumulation of P. chabaudi AS IE in the placentae, in 
significantly higher levels than in the peripheral 
blood [91, 92].This observation recapitulates the 
association of placental sequestration of P. 
falciparum with poor fetal outcome in human pregnancy. 
Infected pregnant females undergoing abortion had a 
widespread placental hemorrhage, thinning of the 
labyrinth and generalized disruption of placental 
architecture. These pathological features were 
abrogated by treatment with anti-TNF. In addition 
maternal blood sinusoids contained fibrin thrombi 
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possibly related to an increase in the expression of 
Tissue Factor and other coagulation factors in 
infected placentas [93, 94]. Taking advantage of the 
established model, Poovassery J. and Moore J.M. went 
on to characterize the cytokine response observed in 
these females upon infection [95].  
Analysis of pro-inflammatory citokine profiles in 
infected pregnant females uncovered that the strong 
systemic inflammatory response is related with 
peripheral parasitemia but does not directly correlate 
with pregnancy outcome and fetal viability.  
A robust immune response characterized by increased 
systemic expression of Inf- and IL10 was observed in 
pregnant and non-pregnant females correlates with 
similar correlation was observed in non-pregnant 
females [95]suggesting this response correlated with  
progression of parasitemia in pregnant females and 
ability to clear infection. Importantly, on G10, when 
infected pregnant mice begin to abort, IFN-γ, IL-10 
and TNF levels did not differ in aborting and non-
aborting mice further suggesting that the systemic 
inflammatory response was dissociated from the 
pregnancy outcome. 
In contrast, the levels of sTNFRII were assessed and 
found to be significantly higher in the plasma of 
infected pregnant mice and further increased in 
females undergoing abortion than in non-aborting 
females suggesting a differential inflammatory 
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response was linked to placental dysfuction and poor 
pregnancy outcome. In vitro testing of fetoplacental 
units or ectoplacental cones from infected pregnant 
females revealed that TNF levels were unexpectedly low 
but sTNFRII expression was increased[93]. 
Additionally, treatment of WT infected pregnant with 
anti-TNF resulted in a significant reduction in the 
resorption rate, reaching the level of pregnant non-
infected females and abrogates main features of 
placental pathology. Thus, the TNF signaling system 
appears to play a critical role in the placenta with 
impact in the pregnancy outcome. These observations 
suggest that fetal trophoblast cells have the 
potential to be immunoactive during malarial infection 
and contribute to a local pathogenic environment in 
the uterus.  
Analysis of Inf- -/- pregnant females that, despite the 
higher levels of parasitaemia and although Inf- -/- 
pregnant females developed pregnancy associated 
malaria, significantly less resorptions were observed 
comparing to WT [93]. This further supports the notion 
that increased susceptibility to infection in pregnant 
females does not correlate with severe PAM pathology 
and pregnancy outcome. Histological examination of the 
infected placentae revealed massive phagocytosis of 
iRBCs and hemozoin by trophoblast giant cells 
resulting, in the absence of maternal IFNγ, in robust 
TNF production. These findings further support that 
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the local production of pro-inflammatory factors is a 
key event in determining placenta pathology.  
Analysis of infection in early pregnancy in the A/J 
mouse further showed that despite increased 
susceptibility to infection inability to maintain 
viable pregnancies were comparable to C57BL/6 mice. 
Peripheral parasitaemia and peripheral levels of TNF 
and IL-1β was significantly higher in A/J than in B6 
mice [92]. But sTNFRII levels in A/J mice show an 
equally significant increase in plasma levels of 
sTNFRII as compared to C57BL/6 mice. This data suggest 
that genetic differences controlling susceptibility to 
infection in pregnant females do not correlate with 
increased severity of PAM. Nevertheless, the 
mechanisms inducing placental pathology appear to be 
heterogeneous as treatment of A/J mice with anti-TNF 
did not ameliorate the rate of abortions [92] as 
observed in the C57BL/6 strain [93]. 
Thus, the models of early pregnancy infection offer a 
tool to follow the systemic response to infection and 
evaluate its relation with placenta pathology and 
pregnancy outcome. Current analysis suggested that 
maternal parasitemia and systemic response appear to 
be dissociated from expression of placenta 
inflammatory components and that interaction of IE 
with the placental tissues underlies placental 
dysfunctions that lead to poor pregnancy outcomes. 
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1.5.3  Mid-term infection 
The relevance of mid-term infections is demonstrated 
by Vinayak V.K. et al. [96] where in a simple 
experiment they show the need of mid-term infections 
in order to be able to follow-up  delivery. Infection 
of Swiss albino pregnant females with the P. berghei 
NICD parasite on day 6 of pregnancy resulted on a 
steep increase of parasitaemia associated with 
maternal death 6 days post infection (G12), well 
before parturition. If pregnant mice were infected on 
day 13 of gestation, parasitaemia curves would follow 
a kinetic similar to non pregnant mice with death 
starting on average 9 days post infection allowing for 
50% of the pregnant females to reach parturition. For 
this 50% that reach term pregnancy, fetuses had 
significantly lower weight than non-infected. From the 
remaining pregnant, 20% had only reabsorptions and 30% 
died before delivery. These results indicate that, 
although 50% of the females reach delivery, foetal 
weight loss and increased reabsorptions characteristic 
of pregnancy associated malaria are observed [96].  
This experiment strongly indicated that in order to 
study the effect Plasmodium infection might have on 
fetuses at delivery, infection should occur at least 
at mid gestation.   
This is indeed what was explored in detail in the work 
by Neres R., et al.[97]. In this model of mid-term 
infection, Balb/c infected with P. berghei ANKA were 
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used to access malaria pregnancy outcome and newborn 
growth. In this study, it is clearly shown that 
infection at mid-gestation reproduces many of the 
features seen in severe human pregnancy associated 
malaria. This included rampant parasitaemia, reduced 
maternal survival to infection, high 
abortion/resorbtion rates and preterm delivery. 
Similar phenotypes were also reported in IRC pregnant 
females infected with lethal P. yoelii [87]. 
Consequences of mid-stage infection in the surviving 
progeny included significantly lower average weight of 
viable fetuses and growth impairment in the first 
stages of post-natal life. 
A more detailed analysis of the pathological features 
of this model revealed a significant thickening and 
disorganization of the placenta labyrinth zone, 
reduction of the vascular space, distention and 
disarrangements of perivascular space and presence of 
IE in the maternal blood space. Some specimens also 
showed focal fibrinoid necrosis in the placental basal 
zone, hyperplasia of syncytiotraphoblasts and 
accumulation of mononuclear cells in the maternal 
blood space composed mainly of monocytes/macrophages. 
Additionally, an ex-vivo adhesion assay of IE binding 
to placental sections strongly suggested, as observed 
for human placentas, a specific CSA sequestration of 
IE to the placental tissue [97].  
55 
 
Taken together, the pathophisiology described in this 
model suggests that mid-gestation infection is a good 
methodology to study terminal foetal outcome and 
placental pathology upon Plasmodium inoculation in 
naïve primigravid pregnant females. 
After the initial characterization of this 
experimental PAM model, and shown its similarities 
with human PAM pathology, further work was developed 
by a different group focusing on a more specific 
dissection of which factors could be involved in this 
pathology. It was shown that placentas from viable but 
low weight fetuses are associated with dysregulated 
angiopoietin expression at both transcriptional and 
protein levels and that this dysregulation preceeds 
the observed malaria-associated foetal growth 
restriction. Serum angiopoietin-1 levels were also 
significantly decreased in infected pregnant mice 
supporting the hypothesis that malaria infection-
associated angiopoietin dysregulation could play a 
pathophysiological role in growth restriction as seen 
in human PAM [98]. Recently, potential links between 
inflammation, angiogenesis alterations, and growth 
restriction in pregnancy-associated malaria have been 
investigated [99], using the mid-term, Balb/c - P. 
berghei ANKA infection model [97]. In this work it is 
proposed that inflammatory cells indirectly generate 
C5a complement fractions that activate monocytes to 
produce soluble vascular endothelial growth factor 
sVEGF, an inhibitor of VEGF. This deregulation of 
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angiogenic factors is hypothesized to disturb the 
developing placental vascularization and as a 
consequence impair placental function and foeatal 
nurturing. 
A different mid-gestation infection model was 
established by Sharma, L. et al.[100] in the Balb/c 
background. In this model the authors chose to use P. 
berghei NK65 infection at gestational day 10. Coherent 
with what is expected, also in this model the levels 
of parasitaemia are significantly higher in pregnant 
females comparing to non-pregnant females infected in 
the same day, with placentae showing sinusoids plugged 
with IE, increased inflammatory cells and malaria 
pigment [100, 101]. This model was established with 
main focus on studying the effects oxidative stress 
may have in placental pathology. It was shown that 
infected pregnant females present higher levels of 
Malondialdehyde (MDA, as index of lipid peroxidation) 
in several organs including placenta [100]. 
Furthermore, there was a decrease in the activity of 
catalase while the levels of the antioxidants reduced 
gluthatione (GSH) and superoxide dismutase (SOD) 
maintained unaltered during pregnancy [101]. This 
increase in ROS could explain the significantly higher 
number of apoptotic cells found in infected placentas 
while the upregulation of Bax, downregulation of Bcl-2 
and increase activity of caspase 3 and 9 suggest the 
involvement of the mitochondrial pathway in  apoptosis 
induction [101]. 
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The mid-gestation infection model represents a 
compromise to study placenta inflammation and 
pathology induced by IE while maintaining maternal 
survival throughout pregnancy. The model is 
particularly useful to study IE-placental interactions 
[76] which is thought to be a key event in triggering 
placental pathology.  
The exploitation of PAM mouse models has helped to 
experimentally reproduce the severity of placental 
pathological manifestations and a spectrum of poor 
pregnancy outcomes. Nevertheless, host cellular and 
molecular components that control the intensity of the 
inflammatory response are still poorly investigated. 
Despite the multitude of Pregnancy Associated Malaria 
mouse models, described in this chapter, none in the 
C57Bl/6 (B6) background allows for the study of 
gestation outcome. The existing models in this mouse 
genetic background were characterized for infections 
at initial gestation, inevitably leading to full 
abortion by mid-gestation. 
Most of the KO mouse strains available are in the 
C57Bl/6 background, offering a precious tool to study 
the role of individual molecules in PAM pathogenesis.  
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1.6 Toll Like Receptors  
- General overview and signalling 
pathways 
Toll-like receptors (TLRs) are type 1 transmembrane 
proteins structurally characterized by extracellular 
leucin-rich repeat (LRR) motifs and a cytoplasmic 
signaling domain known as Toll IL-1 receptor (TIR) 
domain that are joined by a single transmembrane helix 
[102]. TLR ligation leads to the activation of nuclear 
factor-kB (NF-kB) and interferon-regulatory factors 
which lead, respectively, to the production of pro-
inflamatory cytokines and type I interferons.  
Due to sequence similarity [103, 104], TLRs are named 
after the Drosophila melanogaster Toll gene. This gene 
was first identified as a regulator of embryonic 
dorsal-ventral polarity [105] and later was also 
associated with adult Drosophlila melanogaster 
antifungal response [106]. The association of Toll 
with innate immune responses in Drosophila, led to the 
important identification of a human homolog of the 
Drosophila Toll, hToll later named TLR4, and its 
association with the induction of signals for 
activating both an innate and an adaptive immune 
response in vertebrates [107].  
To date, 10 TLRs have been identified in humans (TLR-1 
to TLR-10) and 12 in mice (TLR-1 to TLR-9 and TLR-11 
to TLR-13) [104, 107-112]. 
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Toll-like receptors are categorized as pattern 
recognition receptors (PRRs); germline encoded innate 
immune receptors that were initially described as 
sensors for pathogen associated molecular patterns 
(PAMPs). PRRs can also recognize endogenous molecules 
that are released in response to stress or tissue 
damage. Ligands have been identified for all TLRs with 
the exception of human TLR-10 and mouse TLR-12 and 
TLR-13. TLR3, TLR7 and 8 and TLR9 are located 
intracellularly and are mainly involved in antiviral 
immune responses recognizing dsRNA, ssRNA and CpG DNA 
and haemozoin, respectively. On the other hand, TLR1, 
TLR2, TLR4 to 6 and TLR11, reside at the plasma 
membrane and recognize molecular components located on 
the surface of pathogens. TLR2 forms heterodimers with 
TLR1 or TLR6 and in this form recognizes triacylated 
lipopeptides or diacylated lipopeptides, LTA and 
zymosan. On its own, TLR2 can recognize peptidoglycan 
(a major constituent of Gram-positive bacteria), 
phospholipomannan, tGPI-mucins, haemagglutinin, 
porins, lipoarabinomannan and glucuronoxylomannan. For 
TLR5 and TLR11, depolymerized flagellin and profilin 
are the natural ligands so far identified ([113-120] 
and reviewed in [121, 122]).  
Upon ligand stimulation TLRs signal transduction 
involves either a MyD88-dependent pathway that leads 
to the activation of NF-kB resulting in the 
transcription of pro-inflammatory cytokines and 
chemokines, or a TIR domain containing adaptor 
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inducing IFN-β (TRIF)-dependent pathway resulting in 
the activation of interferon regulatory factor (IRF) 
leading to the secretion of type 1 interferons. For 
the MyD88-dependent signaling pathway, MyD88 interacts 
mith TIRAP (Mal) to recruit members of the IL-1R- 
associated protein kinases (IRAKs), resulting in an 
interaction with tumor necrosis factor receptor 
associated factor 6 (TRAF6). TRAF6 in turn activates 
the TAK1/TAB1/TAB2/3 complex that subsequently 
phosphorilates IkB kinase (IKK)-β and MAP kinase 
(MAPKs). Activation of a complex composed of IKK-α, 
IKK-β and NEMO (NF-kB essential modulator) results in 
the degradation of IkB, allowing NF-kB translocation 
to the nucleus and induction of transcription of NF-kB 
target genes. Simultaneously, MAP kinase activation is 
critical for activation of JNK and AP-1, and thus 
production of pro-inflammatory cytokines as TNF-α, IL-
1, IL-6 and chemokines as IL-8. All TLRs with the 
exception of TLR3 activate the MyD88-dependent 
pathway. 
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Figure 1.8 – Schematic representation of TLR signalling pathway. MyD88-
dependent and TRIF-dependent signalling cascades and resulting 
cytokine/chemokine secretion are depicted. (Figure reproduced under permission 
of author [121]) 
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1.7 TLR4  
Regarding signaling, TLR4 is unique amongst TLRs as it 
is the only able to signal trough either MyD88-
dependent or TRIF-dependent pathways. As for TLR3, the 
TLR4 TRIF-dependent pathway requires the TRAM bridging 
with TRIF resulting in the recruitment of TRAF-6 or 
RIP-1 to activate NF-kB (similar to the MyD88 
pathway). TRIF recruits another signaling complex 
composed of TRAF-3/TBK-1/IKK to phosphorilate IRF, 
leading to their nuclear translocation and induction 
of type I IFN genes [121, 123]. TLR4, as previously 
mentioned, was the first human homolog to the 
Drosophila Toll to be identified and has been one of 
the main focuses on TLR research. TLR4 is mainly known 
for its ability to bind lipopolysaccharide (LPS), a 
major component of the outer membrane of Gram-negative 
bacteria. TLR4 was first identified as an LPS receptor 
by two independent studies as the gene responsive for 
LPS hyporesponsiveness in two TLR4 natural mutant 
mouse strains – C57Bl10/ScCr and C3H/HeJ [124, 125]. 
Besides LPS, TLR4 recognizes several other pathogen 
patterns as VSV glycoprotein G [126], RSV fusion 
protein [127], MMTV envelope protein [128], mannan 
[129] and glucuronoxylomannan [130]. TLR4 is also 
known to recognize endogenous molecules normally 
released upon stress or inflammation such as 
fibrinogen [131], hyaluronic acid [132], β-defensin 
2[133] and HSP60 [134]. 
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At the cell membrane, TLR4 interacts with several 
proteins that facilitate/hamper the signalling 
cascade. Having as an example LPS stimulation of 
mammalian cells, the recruitment of LBP (a soluble 
shuttle protein which directly binds to LPS), CD14 and 
MD-2 to interact with TLR4 are responsible for the 
initiation of the signalling cascade [135].  
Figure 1.9 – Schematic overview of TLR4 signaling upon LPS recognition. 
Recognition is mediated by the TLR4/MD-2 receptor complex, assisted by LBP 
and CD14. LPS mediated TLR4 signalling cascade uses MyD88-dependent and 
MyD88-independent pathways, which lead to the activation of proinflammatory 
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cytokines and Type I interferon genes. (Figure reproduced under permission of 
author [135]) 
 
1.7.1 TLR4 and Malaria 
In addition to the above mentioned molecules 
identified as TLR4 stimulators, the 
glycosylphosphatidylinositol (GPI) anchor glycolipids 
of the Plasmodium parasite [136, 137] have been shown 
to stimulate macrophages trough TLR4 in a MyD88-
dependent fashion (although stimulation trough TLR-2 
also occurs) [138]. This stimulation results in an 
increased secretion of pro-inflammatory cytokines as 
TNF-α and IL-1 [137-139]. In macrophages and 
endothelial cells, P. falciparum GPIs initiate a 
protein tyrosine kinase and protein kinase C-mediated 
signal transduction pathway, regulating inducible NO 
synthase expression with the participation of NF-KB/c-
rel, leading to cell activation and downstream 
production of NO [139]. Dendritic cells (DCs) can also 
be directly stimulated by Plasmodium IE trough TLR4-
MyD88 leading to upregulation of MHC-II, CD86 and 
CD40, NF-kB phosphorilation and secretion of 
proinflammatory molecules as TNF-α and IL-12 [140]. 
Additionally, evaluation of the of impact human TLR4 
polymorphisms (TLR4Asp299Gly and TLR4Thr399Ile) in 
malaria outcome has shown association with increased 
parasitaemia levels in mild malaria patients from 
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Kolkota (west Bengal)[141]. In a Brazilian Amazonian 
population, the TLR4Asp299Gly polymorphism was 
associated with reduced risk for clinical malaria 
[142] and, in Tamale (Ghana), TLR4Asp299Gly and 
TLR4Thr399Ile polymorphisms showed to confer a 1.5 and 
2.6 fold increased risk of severe malaria, 
respectively [143]. As a final remark in the putative 
role of TLR4 might have in malaria outcome, recent 
studies aiming at the development o potent malaria 
vaccines demonstrate the promising adjuvant effect of 
TLR4 agonists [144, 145] 
 
1.7.2 TLR4 and pregnancy 
TLR4 signalling implications in pregnancy outcome have 
been intensively investigated. Several reports on how 
bacterial constituents act trough TLR4 leading to 
inflammation-induced poor pregnancy outcome have been 
addressed in mouse models; LPS administration or 
intravenous bacterial infections during pregnancy 
leads to an increase in foetal death [146, 147], 
preterm delivery [147] and foetal weight loss [148]. 
Necrosis and inflammatory infiltrates composed almost 
entirely of polymorphonuclear leukocytes were apparent 
in the decidua [147, 148], marginal region, labyrinth 
and the membranous yolk sac of WT placentas, while 
significantly reduced in placentas from TLR4
-/- 
pregnant 
females [147].  
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In these studies, systemic blockage of TLR4 signalling 
(either using a TLR4 antagonist [146, 147] or TLR4
-/-
 
mice[147]) significantly reduced the preterm delivery 
percentage [146] and foetal death [146, 147]. 
Nevertheless, no differences in placental bacterial 
load were registered [147]. These results can be 
explained by TLR4 mediated effects on increasing the 
expression of CD86 co-stimulatory molecule in CD45+ 
and CD49b+ peripheral blood lymphocytes (PBLs) as well 
as by increasing the expression of CD69 in CD3+ PBLs 
[146]. Regarding placental immunocytes, increased CD86 
expression on CD45+ cells and increased number of 
CD49b+ CD45+ and percentage of CD69+ NK cells were 
observed. These activation profiles were reverted if 
TLR4 was blocked prior to LPS administration showing 
the specific effect trough TLR4 [146]. In addition to 
the peripheral role of TLR4 in poor pregnancy outcome, 
confocal microscopy and mRNA analysis revealed 
differences in placental TLR4 expression between 
bacteria infected and non infected placentas [148]. 
In humans, it has been shown that peripheral blood 
mRNA TLR4 is significantly increased in women with an 
idiopathic preterm labour in comparison to controls. 
Similarly, the number of TLR4 mRNA copies was 2.2 
times more elevated in women with idiopathic preterm 
labour. Additionally, this increase TLR4 mRNA 
expression was attributed to overexpression in CD14+ 
cells in idiopathic preterm labour women [149].  
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These studies were focused in the role of TLR4 
expression in maternal cells and tissues but the TLR4 
expression in the trophoblast has been neglected or 
put apart. In a study by Klaffenbach and colleagues 
[150] it was shown that highly purified villous 
trophoblasts were not responsive to LPS as detected by 
production of IL-8, IL- 10, or IL-6. On the other hand 
granulocytes, which are closely attached to 
trophoblasts, were the main cells responsible for the 
production antimicrobial proteins upon LPS 
stimulation. 
Despite the references to maternal peripheral blood as 
the exclusive/main participant in TLR4 mediated poor 
pregnancy outcomes and lack of TLR4 expression in 
villous trophoblasts, other studies show moderate to 
strong immunoreactivity for TLR4 protein in 
extravillous trophoblasts and intermediate 
trophoblasts independently of coming from term or 
preterm placentas with or without chorioamnionitis 
(CAM), while no immunoreactivity was detected in 
normal villous trophoblasts [151] as also reported by 
Klaffenbach [150]. 
Interestingly, in this study, villous Hofbauer cells 
(placental macrophages) show a weak reactivity in term 
and preterm placentas without CAM but a moderate to 
strong reactivity in preterm placentas with CAM 
indicating that Hofbauer cells in the villi recognize 
bacterial compounds such as LPS [151]. 
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Knowing that Gram negative bacteria activate TLR4 on 
immune system cells leading to preterm birth (PTB), A. 
Bitner and colleagues [152] evaluated the impact of 
maternal and fetal carriage of TLR4 gene polymorphisms 
on the risk of PTB. In their study, the frequency of 
LPS hyporesponsive TLR4 variants (896A>G, 1196C>T) 
[153] was determined in women who delivered at term 
(after the 37
th
 week of gestation), in women who 
delivered preterm (before the 37
th
 week of gestation) 
and in very-preterm delivery (before the end of the 
33
rd
 week of gestation).  
It was found a statistically significant difference in 
the frequency of TLR4 1196C>T polymorphism between 
mothers who delivered before 33 weeks gestation and 
those who delivered later.  
A further analysis found that the maternal carriage of 
only one of analyzed polymorphisms inside TLR4 gene 
(either 896G or 1196T) does not significantly affect 
the risk of prematurity while simultaneous carriage of 
both examined polymorphisms (896G and 1196T) was 
associated with significant reduction in risk of birth 
before the 33rd week of gestation. Additionally, 
foetuses born before the 37th week of gestation tended 
to have lower TLR4 1196T allele frequency than term 
foetuses[152].  
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1.7.3 TLR4 and Malaria during pregnancy 
TLR4 has also been shown to be involved in pregnancy 
outcomes in the presence of malaria infection. A study 
concerning primiparous women, in southern Ghana,  
examined whether common polymorphisms of TLRs involved 
in response to P. falciparum could influence malaria 
disease outcome during pregnancy. In non-infected 
women, the common TLR4 variants analyzed (Asp299Gly 
and Thr399Ile) had no influence on anemia, LBW, IUGR, 
preterm LBW, or preterm delivery. 
However, while in P. falciparum infected women the 
TLR4 polymorphisms had no influence on the risk of 
placental malaria or placental parasite densities, the 
TLR4 Asp299Gly polymorphism worsened the clinical 
outcomes. This polymorphism was associated with a 6-
fold-increased risk of LBW in term infants and the 
risk of anemia was increased almost 5-fold in P. 
falciparum–infected women with TLR4 Asp299Gly, 
compared with women with the TLR4 wild-type 
allele[154]. 
Together, the current literature strongly implicates 
TLR4 expression/signaling in pregnancy outcome, 
suggesting that TLR4 is implicated in inflammatory 
responses occurring in the placenta. Nevertheless, to 
date, a clarification as to the specific contribution 
of maternal and foetal TLR4 to the observed phenotypes 
has not been addressed. 
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1.8 IFNAR1 
Interferons was first described by Isaac and 
Lindenmann in 1957 [155]. After incubation of heat-
inactivated influenza virus with chick chorio-
allantoic membrane a new factor was released that 
would interfere with the growth of live virus on those 
membranes.  
Since interferons were identified, much research 
effort has been put into understanding their role in 
the immune system. Type I interferons are tightly 
related to viral and tumoral responses, being applied 
as therapies for those pathologies [156-159]. More 
recently, some autoimmune manifestations, as is the 
case of multiple sclerosis and systemic lupus 
erythematosus, have also been targeted by type I 
interferon therapies [160, 161]. 
For long, macrophages have been known as the main 
source of IFNα/β upon viral infection. Stimulation 
with dsRNA, microbial pathogens or microbial products 
such as LPS, strongly induces IFNα/β in this cell 
type. Other sources of IFNα/β include fibroblasts, NK 
cells, T cells, dendritic cells and plasmacytoid 
monocytes [162-164].  
Type I interferons are a family of cytokines coded by 
intronless genes and widely distributed amongst 
vertebrates. The most studied of this cytokine family 
are IFNα and IFNβ (IFNα/β). These comprise more than 
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15 members in humans and mice, with 14 IFNα and one 
single IFNβ subtypes [163, 165, 166]. The type I IFNs 
produce differential activation of genes and cellular 
activities probably due to the differential binding to 
their receptor or differences in receptor subunit 
recruitment by the various type I IFNs [167]. 
IFN α and β exert their function through binding to 
the type I IFN receptor (IFNAR), activating it. IFNAR 
is a heteromeric receptor composed of two cloned 
membrane glycoprotein subunits – IFNAR1 (α) and IFNAR2 
(β), ubiquitously expressed in virtually all cell 
lineages [168, 169]. 
On its own, IFNAR2 has moderate intrinsic affinity to 
all type I IFNs, whereas IFNAR1 alone binds type I 
IFNs weakly. However, IFNAR1 plays an essential role 
in respect to the final high affinity and differential 
ligand specificity of the IFNAR complex [167]. 
Binding of IFN α/β to each IFNAR subunit is followed 
by a JAK-STAT signalling pathway. Briefly, the 
activation of the receptor-associated tyrosine kinases 
Jak1 (Janus kinase 1) and Tyk2 (Tyrosine kinase 2) 
phosphorylate the receptor chains creating docking 
sites for the transcription factors STAT 1 and 2 
(Signal Transducer and Activator of Transcription 1 
and 2). STAT1 and 2 are phosphorylated by the Jaks, 
and form heterodimers. Together with IRF-9 (Interferon 
Regulatory Factor 9), this protein complex forms the 
transcription factor ISGF3 (Interferon-stimulated gene 
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factor 3) which, in turn binds to DNA at the ISRE 
(Interferon Stimulated Response Elements) and induces 
transcription of ISGs (IFN-stimulated genes)[165, 170, 
171]. 
Figure 1.10 –.Schematic representation of IFNAR signaling cascade. (Figure 
adapted and reproduced under permission of authors [172]) 
 
1.8.1 IFNAR1 and Malaria 
IFNAR1 has been reported to be involved in determining 
severity of malaria infection. In humans IFNAR1 
polymorphisms have been associated with disease 
severity and progression to cerebral malaria, 
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especially in children [73, 173, 174]. In mice, IFNAR1 
has been shown to promote sequestration and 
accumulation of CD8
+
 cells in the brain tissue. 
Accordingly, IFNAR1
-/-
 mice show significant protection 
against the development of experimental cerebral 
malaria (ECM) with reduced accumulation of CD8
+
 
lymphocytes [73, 175]. Furthermore, it was 
demonstrated that the specific expression of IFNAR1 in 
CD8
+
 cells, per se, is a critical mechanism for ECM 
development [73]. In addition to the reports on the 
role of IFNAR1 related to adaptive immune responses, 
recent work has revealed its involvement in innate 
parasite sensing [176]. In this work, the authors 
report the existence of a P. falciparum DNA sensing 
pathway alternative to the already well described TLR9 
signaling [177-179]. The authors have found the 
occurence of the AT-rich motif, ATTTTTAC, to be 
extremely high in Plasmodium spp. genome [176]. This 
motif stimulated potent IFN type I responses on HEK293 
cells, mouse macrophages cultures, human PBMC, THP-1, 
mouse splenocytes, fibroblasts, bone marrow-derived 
macrophages and splenic DCs [176]. This new TLR9 
independent pathway acts through an unknown receptor 
coupled to the STING, TBK1 and IRF3-IRF7 signalling 
pathway. Nevertheless, although unknown, this 
Plasmodium sensing pathway is indirectly related to 
IFNAR1 as mice lacking the type I IFN receptor were 
resistant to otherwise lethal cerebral malaria [176]. 
This report involves, for the first time, IFNAR1 in 
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the innate recognition of Plasmodium components 
opening a new perspective on IFNAR1 role in malaria 
immunity. 
 
1.8.2 IFNAR1 and Pregnancy 
There are numerous studies on the effect IFNα/β might 
have in pregnancy outcome, mainly due to the clinical 
applications of such molecules in pregnant women 
suffering from essential thrombocythemia, chronic 
myelocytic leukemia, Hepatitis B and C [180] and 
autoimmune disorders as is the case of multiple 
sclerosis [181, 182]. In these reports mild to no 
influence in miscarriages or foetal malformation are 
detected upon clinical administration of IFNα/β. 
Nevertheless, reports regarding a possible role of 
IFNAR1 during pregnancy in humans and mice are scarce 
with one report involving IFNAR2 in murine in utero 
development [183].  
However, studies in other species indicate a possible 
role for IFNAR1 in pregnancy. In ruminant angulate 
species, IFN-τ, a type I IFN structurally related to 
IFN-α, is secreted by the conceptus trophectoderm 
before definitive trophoblast attachment and 
implantation as a signal for maternal recognition. It 
mediates its effects by acting on the uterine 
endometrium, where it regulates the normal pulsatile 
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production of PGF2α, presumably as a result of its 
binding to type I IFN receptors [184, 185].  
In these studies, both IFNAR1 and IFNAR2 mRNA and 
protein were found to be expressed in endometrial 
luminal epithelium and superficial glandular 
epithelium in pregnant and non-pregnant uteri [186] 
with mild temporal variation of IFNAR1 expression in 
pregnant uteri [184, 187]. Interestingly, IFNAR1 was 
also identified in the conceptuses trophectoderm and 
responded to recombinant bovine IFNτ. This led to 
increased expression of ISGs indicating that IFNτ can 
also act as an autocrine factor to regulate foetal 
trophectoderm cell proliferation [185]. 
Although not expressed in humans, molecular 
interactions between bovine IFN-τ1c and human IFNAR1 
are theoretically possible [188] and ovine IFN-τ has 
been shown to confer resistance to HIV-1 infection in 
human macrophages [189].  
Taken together such observations allow us to speculate 
a possible role of foetal IFNAR1 in human and or 
murine pregnancy and specifically to hypothesize a 
role for IFNAR1 in pregnancy associated malaria. 
Despite no significant attention has been put towards 
the role of IFNAR1 in pregnancy outcome, PAM and ECM 
share common features as is the case of IE 
adhesion/sequestration [190-193], tissue recruitment 
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of pro-inflammatory cells [73, 194, 195] and tissue 
damage [196-199]. 
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1.9 Objectives 
The overall goal of this thesis was to evaluate the 
role of specific innate immunity factors in murine 
pregnancy associated malaria, namely Tlr4 and Ifnar1. 
To this end the specific objectives were: 
 
1- To establish new mouse models that allow analysis 
of PAM gestational outcome in the context of mid 
gestation infection in the C57BL/6 background. 
2- To dissect maternal and foetal genetic 
contributions to PAM outcomes focusing on Tlr4 
and Ifnar1.  
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All data analysis referring to the above mentioned 
parasites was performed by me, with the exception of 
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K173 were performed by Luciana Vieira de Moares. 
Manuscript was written by me, Luciana Vieira de Moraes 
and Carlos Penha-Gonçalves. 
Blandine Franke-Fayard and Chris J. Janse provided 
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2.2 Abstract 
Background: Placental malaria (PM) is one major 
feature of malaria during pregnancy. A murine model of 
experimental PM using BALB/c mice infected with 
Plasmodium berghei ANKA was recently established, but 
there is need for additional PM models with different 
parasite/host combinations that allow to interrogate 
the involvement of specific host genetic factors in 
the placental inflammatory response to Plasmodium 
infection. 
Methods: A mid-term infection protocol was used to 
test PM induction by three P. berghei parasite lines, 
derived from the K173, NK65 and ANKA strains of P. 
berghei that fail to induce experimental cerebral 
malaria (ECM) in the susceptible C57BL/6 mice. 
Parasitaemia course, pregnancy outcome and placenta 
pathology induced by the three parasite lines were 
compared. 
Results: The three P. berghei lines were able to evoke 
severe PM pathology and poor pregnancy outcome 
features. 
The results indicate that parasite components required 
to induce PM are distinct from ECM. Nevertheless, 
infection with parasites of the ANKAΔpm4 line, which 
lack expression of plasmepsin 4, displayed milder 
disease phenotypes associated with a strong innate 
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immune response as compared to infections with NK65 
and K173 parasites. 
Conclusions: Infection of pregnant C57BL/6 females 
with K173, NK65 and ANKAΔpm4 P. berghei parasites 
provide experimental systems to identify host 
molecular components involved in PM pathogenesis 
mechanisms. 
 
 
 
 
Keywords 
P. berghei, placental malaria, cerebral malaria, 
placental pathology, TNF-, TLR4, TLR2 
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2.3 Background 
Organ pathology evoked by Plasmodium infections often 
correlates with accumulation of infected erythrocytes 
in specific organs leading to severe clinical 
manifestations as is the case of respiratory distress, 
cerebral malaria (CM) and severe placental malaria 
(PM) [1]. PM is one major feature of malaria during 
pregnancy and is usually associated with low birth 
weight due to intra-uterine growth retardation and/or 
preterm delivery ([2] and reviewed in [3]), 
stillbirths, maternal anaemia and mortality [4, 5]. 
Placental malaria results from accumulation of 
parasitized erythrocytes that is associated with a 
prominent monocytic inflammatory response that entails 
increased IFN-γ and TNF production and enhanced levels 
of monocyte/macrophage recruiting factors (MIP-1α and 
MIP-1β) [1, 6]. Placental malaria pathology includes 
maternal-foetal barrier thickening, disorganization 
and destruction of placental tissue, proliferation of 
cytotrophoblastic cells and excessive perivillous 
fibrinoid deposits usually associated with focal 
syncytiotrophoblastic necrosis [7-10]. The severity of 
placental pathological manifestations is associated 
with a spectrum of severe pregnancy outcomes but the 
host cellular and molecular components that control 
the intensity of the inflammatory response are still 
not well-defined and are difficult to investigate in 
pregnant women.  
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An experimental system where P. berghei ANKA evokes a 
syndrome that resembles severe PM in women was 
established in a experimental cerebral malaria (ECM)-
resistant mouse strain (BALB/c) allowing experimental 
investigation of PM pathogenesis in the mouse. Low 
foetal viability and increased maternal disease 
severity correlate with placenta pathology that, in 
this experimental model, is characterized by 
thickening of the placental barrier in the labyrinth 
zone and tissue damage, accumulation of 
monocyte/macrophages and enhanced expression of pro-
inflammatory, apoptosis and oxidative stress factors 
[11-13]. The use of the P. berghei model of malaria 
for analysis of PM would benefit by development of 
additional experimental tools. Access to numerous 
(C57BL/6) mouse mutants would allow interrogating the 
involvement of host genetic factors in the placental 
inflammatory response to Plasmodium infection. 
Recently, the C57BL/6 mouse strain in combination with 
the rodent parasite Plasmodium chabaudi has been 
exploited to study pregnancy malaria pathogenesis with 
infection initiated early in gestation [14, 15]. Here, 
different parasite lines derived from the P. berghei 
strains K173, NK65 and ANKA Δpm4 [16] that are not 
able to induce ECM in C57BL/6 mice, were used to 
establish additional placental malaria experimental 
models in this mouse strain. The results show that 
pregnant mice infected with the three lines develop PM 
indicating that P. berghei parasite factors that are 
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responsible for inducing ECM in the C57BL/6 mouse are 
not required to induce placental pathology and poor 
pregnancy outcome in female mice infected during 
pregnancy. These experimental systems are valuable 
tools to study host and foetal genetic factors in the 
pathogenesis of placental response to Plasmodium 
infection. 
 
2.4 Methods 
2.4.1 Mice and pregnancy monitoring 
Eight to twelve week-old C57BL/6 mice were obtained 
from the animal facility at Instituto Gulbenkian de 
Ciência. Mice were bred and maintained under 
specificpathogen free (SPF) conditions. C57BL/6 
females were transferred to a cage with one isogenic 
male (two females: one male) and removed after 48 
hours. The day the females were removed was considered 
gestational day 1 (G1). Pregnancy was monitored every 
other day by weighing females. Successful 
fertilization was confirmed between G10 and G13 when 
animals had an average increase of 3 to 4 g in body 
weight. Abrupt weight loss after G13 was an indicator 
of unsuccessful pregnancy. Animal housing and all 
procedures were in accordance with national 
regulations on animal experimentation and welfare and 
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approved by the Instituto Gulbenkian de Ciência Ethics 
Committee. 
 
2.4.2 Parasites and infection 
The following parasite lines were used in this study: 
i) a reporter parasite line of the K173 strain/isolate 
of P. berghei which expresses the reporter protein 
GFPluciferase under the control of the schizont-
specific ama-1 promoter. This mutant (line 1272cl1) 
has been generated in the K173cl1 line [15]. The gfp-
luciferase gene has been integrated into the c/d-ssu-
rRNA unit by double cross-over integration without a 
drug selectable marker. Details of this line can be 
found in the RMgmDB database[17]; ii) a mutant of P. 
berghei ANKA which lacks expression of plasmepsin-4 
(ANKAΔpm4; line 1092cl4; RMgmDB-316) and expresses the 
reporter fusion protein GFP-luciferase under the 
control of the ama-1 promoter [16]; iii) a parasite 
line originally derived from the P. berghei isolate 
NK65 at New York University and kindly provided by Dr 
Maria Mota (Instituto de Medicina Molecular, Lisbon, 
Portugal). Infections in Figure 1 were performed by 
intraperitonial (i.p.) injection of 10
6
 infected 
erythrocytes (IE). Parasitized red blood cell 
preparations were obtained from one in vivo passage in 
C57BL/6 mice, when the percentage of infection reached 
approximately 10%. Pregnant mice were intravenously 
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(i.v.) injected with 10
6
 infected erythrocytes. 
Infection with ANKAΔpm4 at G13 yielded very low 
parasite burden during pregnancy due to reduced 
multiplication rate of this parasite [16], but 
infection at G10 allowed significant parasite 
expansion within pregnancy time. Thus, infection was 
performed on G10 (ANKAΔpm4 IE) or G13 (P. berghei K173 
or NK65 IE). Parasitaemia was measured by flow 
cytometry [18] to detect infected erythrocytes stained 
with DRAQ5 (Biostatus Limited). The labelling of 
infected red blood cells with DRAQ5 is an adaptation 
of the manufacturer’s protocol for cell cycle analysis 
by flow cytometry. Briefly, a drop of blood was 
collected by tail pinching of infected mice into 400 
μl of FACS Buffer (PBS 1x, 2% FBS, sodium azide 
0.02%). DRAQ5 was added directly to the collected 
samples at a final concentration of 1μM. Samples were 
vortexed to allow an appropriate incorporation of 
DRAQ5 into the parasite DNA and immediately analysed. 
Uninfected red blood cells do not stain positive for 
DRAQ5 as they are devoid of DNA content. Parasitaemia 
was expressed as % of stained cells within the 
erythrocyte morphological gate. ECM development was 
monitored from day 5 post-infection (PI) as including 
one or more of the following neurological symptoms; 
head deviations, paralysis, ataxia and convulsions 
[19].  
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2.4.3 Pregnancy outcome and foetal 
survival 
Infected pregnant mice were killed by CO2 narcosis and 
subjected to caesarian section on G18 (K173 or NK65 
infection) or G19 (ANKAΔpm4 infection) and 
stillbirths, foetal weight, foetal survival at 
delivery and placental pathology were evaluated. 
Foetuses were extracted from their amniotic envelop 
and viability was immediately evaluated by reactive 
movement to touching with pliers. The lack of prompt 
movement indicated that the foetus had recently died. 
Reabsorptions were identified as small implants with 
no discernible foetus and placenta, corresponding to 
embryos that died before complete placenta 
vascularization. Viable and non-viable foetuses were 
weighed and counted. Non-viable (dead foetuses plus 
reabsorptions) foetuses were recorded as stillbirths. 
Viable foetuses were killed combining hypothermia and 
CO2 narcosis. In another set of experiments, infected 
pregnant mice were allowed to deliver in order to 
access litter size and newborns viability. Foetuses 
that have been expelled before the gestational day of 
analysis were also recorded as dead newborns. Non-
infected pregnant mice were used as controls. 
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2.4.4 Placenta preparations and 
morphometric analysis 
Placentas from infected and non-infected females 
sacrificed on the same gestational day were equally 
treated. Each placenta was separated in two halves: 
one half was fixed in 10% formalin for further 
histological processing and the other half collected 
in lysis buffer (RNeasy Mini Kit - Qiagen) 1% β-
mercaptoethanol for RNA extraction. Paraffin-embedded 
non-consecutive placenta sections were stained with 
hematoxylin-eosin (HE). HE-stained placental sections 
were analysed for histopathology and vascular space 
quantification. In each section, three randomly 
selected microscopic fields in the labyrinthine region 
(magnification 400x) were acquired at 12 Mpixels 
resolution, using a colour video camera (AxionCam HRc, 
Zeiss) connected to a light microscope (Axion Vision, 
Imager.M2, Zeiss). To quantify vascular spaces only, 
areas that presented accumulation of glycogen cells, 
necrosis or thrombi were excluded. An image analysis 
routine using ImageJ (ImageJ 1.37v, National 
Institutes of Health) was implemented. Briefly, after 
acquisition, the images underwent an automated light 
analysis procedure where noise removal was applied to 
ensure colour and image quality standardization across 
sections and specimens. Images were given a colour 
threshold to cover the area corresponding to blood 
spaces lumen. The coverage percentage was calculated 
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as the ratio between the number of pixels covered by 
the area defined by the threshold and the overall 
number of pixels in the image. The blood vascular area 
in each placenta was estimated from the analysis of 
three nonconsecutive sections. Two independent 
observers analysed the placentas one of which was 
unaware of the samples identification. Results were 
reported as the average of counts obtained by the two 
observers. 
 
2.4.5 RNA isolation and gene expression 
analysis 
Total RNA from individual placentas was obtained using 
an RNeasy Mini Kit (Qiagen), following the 
manufacturer’s instructions for animal tissues. One 
microgram of total RNA was converted to cDNA 
(Transcriptor First Strand cDNA Synthesis Kit, Roche) 
using random hexamer primers. Ccl2, Ccl3, Tlr2, Tlr4 
and TNF expression was quantified using TaqMan Gene 
Expression Assays from ABI (Mm00441242_m1, 
Mm00441258_m1, Mm00442346_m1, Mm00445273_m1, 
Mm00443258_m1, respectively). For P. berghei ANKA 
quantification specific primers for Taqman were, 
Forward 5’-CCG ATA ACG AAC GAG ATC TTA ACC T–3’, 
Reverse 5’- CGT CAA AAC CAA TCT CCC AAT AAA GG-3’ and 
Probe 5’– ACT CGC CGC TAA TTA G -3’ (FAM/MGB). The 
endogenous control Gapdh (Mouse GAPD Endogenous 
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Control, ABI) was used in multiplex PCR with target 
genes. PCR reactions were performed with ABI Prism 
7900HT system. For TaqMan assays, ΔCt was calculated 
by subtracting the cycle threshold (Ct) of the target 
gene from the GAPDH and relative quantification was 
obtained with normalization by GAPDH. Results were 
plotted as fold change over the respective non-
infected controls. 
 
2.4.6 Statistical analysis 
Survival curves were compared using the Log-Rank test 
(Mantel-Cox). Parasitaemia data were presented as mean 
values +/- SEM. Unpaired t test (Welch´s correction) 
was performed in comparison of each parasite line with 
the respective control group. Kruskal-Wallis non-
parametric test with Dunn’s post-test was used for 
comparisons between the three infected groups. Data 
were considered significant when p<0.05. 
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2.5 Results 
2.5.1 Increased parasitemia in pregnant 
mice 
As opposed to the canonical strain P. berghei ANKA, 
parasites of the NK65 isolate and of mutant ANKAΔpm4 
have been previously described not to cause 
experimental cerebral malaria (ECM) in the C57BL/6 
susceptible strain [13, 14]. Similarly, the K173cl1 
line derived from the K173 isolate has lost the 
capacity to induce ECM [unpublished results, CJJ and 
BF]. The course of infection by the three parasite 
variants in non-pregnant C57BL/6 females (Figure 1) 
showed that differently from wild-type P. berghei ANKA 
the three parasite lines do not induce the 
characteristic features of ECM. Nevertheless they 
induced hyperparasitaemia leading to a fatal outcome. 
P. berghei ANKAΔpm4 and NK65 exhibited slower growth 
kinetics when compared to the K173 line and 
corresponding delayed effects on the survival rate. To 
ascertain the effect of infection in pregnancy, mice 
were infected with K173 and NK65 at G13 when placenta 
vascularisation is established while infection with 
ANKAΔpm4 was performed at G10 due to reduced 
multiplication rate of this parasite [16]. Pregnant 
mice did not exhibit symptoms of ECM but showed higher 
parasitaemia across time as compared to non-pregnant 
females, reaching 20% at 5 to 9 days after infection 
(Figure 2) and indicating that parasites of the three 
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lines show increased ability to cause 
hyperparasitaemia during pregnancy. 
Figure 1- Susceptibility to infection of C57BL/6 mice. (A) Timecourse 
parasitaemia and (B) survival of P. berghei K173, NK65 and ANKAΔpm4 in 
C57BL/6 non-pregnant mice. Animals were infected i.p. with 106 IE. Parasitaemia 
of DRAQ-5 labelled samples was followed by FACS. In (B) survival curves were 
compared using the Log-Rank (Mantel-Cox) test. Statistical significance results 
were p<0.01 when comparing K173 vs NK65 or ANKAΔpm4; p<0.05 when 
comparing NK65 to ANKAΔpm4. 
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Figure 2- Maternal susceptibility to infection. (A) Time-course parasitaemia of 
P. berghei K173 (A), NK65 (B) and ANKAΔpm4 (C) in C57BL/6 pregnant and non-
pregnant females. Animals were infected i.v. with 106 IE at G13 (A, B) or at G10 
(C). Highlighted area corresponds to G18 (A, B) or G19 (C). Parasitaemia of 
DRAQ-5 labelled samples was followed by FACS. Unpaired t test (Welch´s 
correction) *p<0.05; ** p<0.01; ***p<0.001. 
 
2.5.2 Impaired pregnancy outcome  
The impact of infection in the pregnancy outcome was 
ascertained by the frequency of stillbirths in utero 
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as well as foetal weight at G18 in pregnant females 
infected with NK65 and K173 or at G19 in ANKAΔpm4 
infected mice. Intra-uterine foetal death was 
increased in pregnancies of NK65-infected mice (69% of 
the females had a high number of non-viable foetuses), 
Figure 3- Stillbirths and underweight foetuses as consequence of infection. 
C57BL/6 pregnants were infected i.v. on G13 (K173 or NK65) or on G10 
(ANKAΔpm4) with 106 IE. Number of stillbirths (dead foetuses and/or 
reabsorptions) per mother in utero (A) and viable and non-viable foetuses 
weight (B) were accessed at G18 or G19. **p<0.01; ***p<0.001; NI: non-
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infected. Cut-off for non-viability was established in non-infected pregnant mice 
(dashed line). 
in K173-infected mice (62%) and in ANKAΔpm4 infected 
pregnants (25%) when compared to non-infected controls 
(Figure 3A and Additional file 1). Viable and non-
viable foetuses from NK65, ANKAΔpm4 and, to a lesser 
extent, from K173- infected mothers showed 
significantly reduced weight as compared to non-
infected controls at the same gestational day (Figure 
3B). Moreover, newborn viability at delivery was 
strikingly reduced (Table 1) as compared to non-
infected pregnant females. In some instances NK65 
infection provoked maternal death during pregnancy 
(Table 1). These results show that infection of 
C57BL/6 pregnant females with P. berghei-derived 
parasite lines that fail to induce ECM, recapitulate 
with different degrees of severity the features of PM  
Table I Newborn reduced viability after maternal infection during 
pregnancy 
 NI K173 NK65 ANKAΔpm4 
Number of mothers 5 4 3* 4 
Number of newborns 40 24 16 22 
Nr. Dead newborns (%) 2 (0.5) 22 (91.6) 16 (100) 15 (68) 
NI: non-infected; * Number of surviving mothers from a initial group of 5. 
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described in BALB/c mice infected P. berghei ANKA [11, 
12] namely, intrauterine growth retardation and poor 
pregnancy outcome. Nevertheless, it was clear that 
infection with ANKAΔpm4 had milder effects on 
pregnancy outcome. 
 
2.5.3 Placental pathology in C57BL/6 
mice 
Next, infected placentas were examined for 
pathological features typical of PM including 
syncytiotrophoblast thickening, tissue destruction, 
fibrin deposits, thrombi formation and reduction of 
maternal blood space [12]. HE-stained sections 
displayed variable degrees of localized trophoblast 
layer thickening, placental tissue disorganization 
(Figure 4 B-D) and associated necrosis foci in the 
labyrinth zone and thrombi (Figure 4E) as compared to 
non-infected placentas (Figure 4A). Morphometric 
analysis of the labyrinth zone revealed a significant 
reduction in the available area for maternal blood 
circulation in all infected groups when compared 
tonon-infected controls but NK65-infected mothers 
showed the highest restriction in blood space area 
Figure 4F). Thus, the severity of placental 
pathological alterations evoked by the three parasite 
lines is distinct which corroborated the observed in 
pregnancy outcome. Notwithstanding the observed 
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Figure 4. Placental histology of labyrinth zone and morphometric analysis. 
Representative photomicrograph of H&E stained placental sections of non-
infected (NI) (A), K173 (B), NK65 (C) and ANKAΔpm4 infected pregnant mice 
(D). (E) Histological sections show necrotic foci (arrow) and thrombi 
(arrowhead) in placentas infected with ANKAΔpm4 (upper picture) and K173 
(lower picture) parasites. (F) Relative quantification of vascular space using an 
automated morphometric procedure in H&E stained sections evaluated in 
placental sections. Mice were infected i.v. with 10
6
 P. berghei K173 or NK65 IE 
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(G13) or ANKAΔpm4 IE (G10); placentas were excised on G18 (K173 and 
NK65) or G19 (ANKAΔpm4). Scale bar: 20 μm; in (F) line refers to mean; 
*p<0.05;**p<0.01; ***p<0.001. 
differences in pregnancy outcome and placenta 
pathology, the infection with these three parasite 
lines did not result in significant differences in 
placental parasite burden (Figure 5). These results 
indicate that despite the observed differences in 
placental pathology and pregnancy outcome, the ability 
to accumulate in the placenta is not significantly 
different between the three P. berghei lines. 
Figure 5- Placental parasite burden. Placentas were collected at G18 (K173 
and NK65) or G19 (ANKAΔpm4) and RNA expression of P. berghei was 
evaluated by qReal Time PCR. ΔCT was calculated by subtracting the cycle 
threshold (Ct) of the target gene from the GAPDH. Dunn´s Multiple Comparison 
Test, p>0.05 (n.s.). 
 
122 
 
2.5.4 Differential patterns of placental 
inflammation 
To investigate the differences in pregnancy outcome 
and placental immune response to infection elicited by 
the three P. berghei lines, gene expression of 
proinflammatory molecules and informative markers of 
innate and adaptive immune responses in infected  
Figure 6- Placental gene expression of inflammatory factors. Placentas were 
collected at G18 (K173 and NK65) or G19 (ANKAΔpm4) and RNA expression 
of Ccl2, Ccl3, Tlr2, Tlr4 and Tnfα were evaluated by qReal Time PCR. Relative 
quantification (RQ) was obtained with normalization by GAPDH. Results are 
plotted as fold change against non-infected controls collected at the same 
gestational day (G18 versus K173 or NK65 and G19 versus ANKAΔpm4); Line 
refers to median values. Kruskal-Wallis Test **p<0.01; ***p<0.001 refers to 
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differences between different parasite lines; Unpaired t test 
#
p<0.05; 
##
p<0.01; 
###
p<0.001 compares each parasite line to its respective non-infected control. 
relative to non-infected controls were studied (Figure 
6 and Additional file 2). Expression of Ccl2 (MCP-1), 
Ccl3 (MIP-1 α), Tlr (Toll-like receptor) 2 and Tlr4 as 
well as Tnf was up-regulated in ANKAΔpm4-infected 
placentas as compared to the other parasite lines. 
Conversely, placentas of K173- and NK65-infected 
females exhibited less reactive inflammatory response. 
This strongly suggests that ANKAΔpm4 infection elicits 
an inflammatory response with a strong innate immunity 
component, which was not observed with parasites of 
the K173 and NK65 lines. Taken together, these results 
suggest that mechanisms involved in PM induction and 
progression might be different amongst different P. 
berghei lines and that these differences are not 
associated with the parasite burden in the placenta. 
 
2.6 Discussion 
Mouse models amenable to genetic dissection of host 
factors of PM pathogenesis were established by 
analyzing the severity of maternal infection, 
pregnancy outcome, placental pathology and the 
expression of inflammatory factors following infection 
with three P. berghei lines that do not induce 
cerebral malaria in the C57BL/6 mouse. The results 
provide evidence that infection of pregnant females 
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with these P. berghei lines induces PM typical 
features, strongly suggesting that parasite factors 
determining cerebral malaria are not required to 
develop placental infection. Nevertheless, the three 
parasite strains induced different degrees of 
placental pathology and impaired pregnancy outcome 
suggesting that parasite factors could underlie a 
spectrum of PM manifestations and distinct 
pathogenesis mechanisms. Thus, NK65 parasites induced 
the most severe syndrome comprising significantly 
lower foetal weight and decreased placental vascular 
area, higher percentage of nonviable foetuses per 
mother and lower number of live newborns. In addition, 
NK65 was the only parasite line causing maternal death 
before delivery (Table 1). Despite similar maternal 
parasitaemia in NK65 and K173-infected pregnant mice, 
the latter presented milder effects in placental 
pathology and in foetal weight loss. On the other 
hand, ANKAΔpm4 infection led to lower stillbirth 
incidence and increased newborn viability compared to 
the other strains. These observations support the 
notion that different P. berghei lines show distinct 
patterns of PM. In fact, an heterogeneous and wide 
range of clinical manifestations is also observed in 
women that have malaria during pregnancy, including 
increased levels of parasitaemia [20-23], increased 
number of abortions, preterm delivery, intrauterine 
growth retardation, low birth weight, maternal 
mortality [24-28] and structural placenta alterations 
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such as trophoblast thickening and consequent vascular 
space reduction [7, 29]. Thus, the different P. 
berghei lines represent a fine-tuning resource in 
constructing experimental systems to study different 
aspects of pregnancy associated malaria pathogenesis. 
It is widely accepted that accumulation of IE is a key 
event in the pathogenesis of severe disease as is the 
case of respiratory distress, CM and severe PM [1]. 
The experiments here presented confirmed that PM 
development was associated with parasite accumulation 
in the placenta. Nevertheless, the parasite burden in 
the placenta was not a major determinant of PM 
severity as the distinct pathology patterns observed 
in mice infected with NK65, K173 and ANKAΔpm4 did not 
correlate with differences in placenta parasite 
accumulation. In particular, infection with the 
ANKAΔpm4 line showed a lower impact on foetal 
viability despite a similar parasite burden in the 
placenta. An earlier report shows that, ANKAΔpm4 
parasites failed to induce disease in an ECM model but 
the resistance phenotype was correlated with lower 
parasite accumulation in the brain compared to wild-
type P. berghei ANKA parasites. This virulence 
attenuated effect was also observed in ECM-resistant 
mouse strains where self-resolving infection was 
associated to antibody-mediated response [16]. 
Nevertheless, this protective effect was not observed 
in ANKAΔpm4-infected pregnant mice although foetal 
viability was increased and correlated with a strong 
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innate immune response. This raises the possibility 
that the vigorous local innate response in ANKAΔpm4 
infected placentas deterred the progression of 
placental tissue disorganization at least for a short 
period warranting an improved pregnancy outcome. 
Although expression of pro-inflammatory markers was 
less stimulated in K173- and NK65-infected placentas 
at G18 it is not ruled out the possibility that gene 
expression differences are not exclusively parasite 
line-related but could also be influenced by 
differences in parasite kinetics as parasite expansion 
in pregnant ANKAΔpm4 mice was somewhat slower as 
compared to K173 and NK65. Thus, the observed 
differences in immune responses might also be 
influenced by the longer exposure of the maternal 
immune system to ANKAΔpm4 (G10 to G19) as compared to 
K173 and NK65 parasite lines (G13 to G18). 
Nevertheless, the PM protracting effects observed in 
ANKAΔpm4 infection offer now interesting research 
perspectives. This experimental model can be used to 
(1) discriminate between the effects exerted by 
foetal- and maternal-derived inflammatory factors in 
PM pathogenesis and (2) to ascertain whether innate 
immune responses can be used to provide effective 
foetal protection in PM. 
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2.7 Conclusions 
The experiments here presented made used of three 
different P. berghei lines and show that parasite 
components that induce pathology during pregnancy are 
distinct from those that induce experimental cerebral 
malaria. In addition, the data indicate that PM 
pathology in ANKAΔpm4 infected mice is associated with 
an inflammatory response with strong innate immune 
component, which was not observed in K173- and NK65-
infected pregnant mice. The characterization of 
different experimental systems of PM in the C57BL/6 
mouse will allow interrogation of genetically modified 
mice to ascertain the role of host molecules in PM 
pathogenesis and to dissect foetal and maternal 
contributions in placental pathology. 
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2.9 Supplementary Figures 
Supplementary Figure1. Gene expression of inflammatory factors in non-
infected placentas. Placentas from healthy pregnant females were collected at 
G18 or G19 and RNA expression of Ccl2, Ccl3, Tlr2, Tlr4 and Tnfα genes were 
evaluated by qReal Time PCR. Relative quantification (RQ) was obtained with 
normalization by GAPDH. *p<0.05. 
Supplementary Table 1. Infection during pregnancy increases the percentage of 
stillbirths  
 
 
Number of 
mothers 
Number of 
stillbirths 
% stillbirths 
/mother 
Non-infected 6 4 0,67 
K173 13 64 4,92 
NK65 16 91 5,69 
ANKA∆pm4 8 14 1,75 
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derived TLR4 and IFNAR1 in 
experimental Pregnancy-Associated 
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3.2 Abstract 
Pregnancy Associated Malaria is an exquisite form of 
Plasmodium infection that frequently leads to poor 
pregnancy outcomes. Although innate immunity responses 
are thought to contribute to the development of 
placental inflammation, the contribution of foetal 
derived factors to clinical PAM outcomes have not been 
addressed. We investigated the role of Tlr4 and Ifnar1 
genes in a model of mouse PAM using heterogenic 
pregnancy strategies that allowed the dissection of 
maternal and foetal-derived contributions to PAM. We 
found that maternal TLR4 contributes to poor foetal 
outcomes but does not impact parasite burden. 
Unexpectedly, foetal TLR4 acted to protect foetal 
viability and to mediate infected-erythrocytes uptake 
by trophoblasts in primary cultures but did not 
influence expression of inflammatory markers 
expression or pathological features of placental 
malaria. On the other hand, maternal IFNAR1 
contributed to increase peripheral and placental 
parasitemia and enhanced foetal loss while foetal-
derived IFNAR1 conferred resistance to placental 
infection but did not protect the foetal viability. 
This work identified maternal Tlr4 and Ifnar1 as 
pathogenesis factors in PAM and uncovered the opposing 
role of their foetal counterparts in conferring foetal 
viability protection or placental infection 
resistance. These findings uncouple placenta parasite 
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burden and foetal protective mechanisms, highlighting 
that foetal viability in infected placenta can be 
controlled by foetal-derived innate immunity factors 
that may provide new approaches to prevent foetal loss 
and lessen severe clinical outcomes of PAM. 
 
 
 
 
Keywords 
Pregancy-Associated Malaria, Tlr4, Ifnar1, heterogenic 
pregnancy, foetal viability  
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3.3 Background 
Pregnancy Associated Malaria (PAM) is often linked to 
severe clinical manifestations including high risk for 
maternal anemia, foetal abortion, premature delivery 
and underweight babies [1-5]. Placental Malaria (PM) 
is a central pathological feature in determining poor 
pregnancy outcomes and is characterized by the 
adhesion of infected erythrocytes (IE) to the fetal 
trophoblast layer [6, 7]. Accumulation of IE in the 
intra-placental maternal blood spaces correlates with 
recruitment of inflammatory cells, monocytes and 
macrophages, and production of pro-inflammatory 
mediators. Increased IFN- and TNF-α production and 
enhanced levels of monocyte/macrophage recruiting 
factors (MIP-1 and MIP-1β) have been detected in 
infected placentas [8, 9]. The local inflammatory 
process consequently leads to placental tissue 
disorganization that is often correlated with 
placental dysfunction and impaired foetal development 
[8, 10-12].  
The severity of placental pathology is associated with 
a spectrum of severe pregnancy outcomes but the host 
cellular and molecular components that control the 
intensity of the inflammatory response are still ill 
defined. Nevertheless, molecules known to be involved 
in the host response to the malaria parasite could be 
involved in placental dysfunction. One such candidate 
is TLR4. Plasmodium glycosylphosphatidylinositol (GPI) 
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[13, 14] has been shown to stimulate macrophages, 
dendritic cells and endothelial cells trough TLR4, 
resulting in increased secretion of pro-inflammatory 
cytokines such as TNF-α, IL-1 and IL-12 [14-17]. Human 
genetic studies have associated TLR4 polymorphisms 
with parasitaemia levels in mild malaria patients 
[18], risk for clinical malaria [19],risk of severe 
malaria [20], risk of maternal anemia risk and low 
birth weight in term infants [21]. Bacterial 
infections have been shown to cause placental 
inflammation and poor pregnancy outcomes in a TLR4 
dependent manner [22, 23]. Increase foetal death [23, 
24], preterm delivery [23] and foetal weight loss [22] 
was observed in WT but not Tlr4
-/- 
females exposed to 
bacterial infections. In these females, systemic 
blockage of TLR4 signaling significantly reduced 
preterm delivery percentage [24] and foetal death [23, 
24]induced by bacterial infection. Interestingly, 
absence of TLR4 expression had no impact on placental 
bacterial load suggesting that foetal protection 
mechanisms are independent of infection intensity[23]. 
Nevertheless bacterial infection favored increased 
placental TLR4 expression, suggesting that TLR4 
signaling participates in the placental response to 
infection [22]. In addition, it has been shown that 
peripheral blood mRNA TLR4 is significantly increased 
in women with idiopathic preterm labor and TLR4 
protein is expressed in trophoblasts [25]. TLR4 gene 
maternal and fetal gene variants were associated to 
141 
 
preterm delivery [26] suggesting  a possible role for 
placental TLR4 expression in pregnancy disturbances. 
Recent work has proposed that malaria innate immune 
responses through TLRs and other putative sensors lead 
to up-regulation of Type 1 Interferon (IFN-I) 
stimulatory genes [27]. Strong evidence supports a 
multi-functional role of IFN-I in during P. berghei 
infection due to the large increase of IFN-stimulated 
genes and up-regulation of essential gene components 
of the IFN signaling pathway, such as signal 
transducers and the IRF family [28]. 
Interferon type 1 Receptor (IFNAR1) gene polymorphisms 
have been associated with disease severity and 
progression to cerebral malaria, especially in 
children [29-31]. Ifnar1
-/-
 mice show significant 
protection against the development of experimental 
cerebral malaria (ECM) with reduced accumulation of 
CD8
+
 T cells [31, 32]. Furthermore, it was demonstrated 
that the specific expression of IFNAR1 in CD8
+
 T cells 
might, per se, be a triggering mechanism for ECM 
development [31]. ECM and PM share pathogenesis 
features such as IE adhesion/sequestration [33-36], 
tissue recruitment of pro-inflammatory cells [12, 31, 
37] and tissue damage [38-41]. The involvement of 
IFNAR1 both in innate and adaptive responses to the 
malaria parasite warrants the evaluation of its role 
in PAM. 
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Here we investigated the role of TLR4 and IFNAR1 in a 
model of experimental PAM using genetically 
heterogeneous pregnancies to discern whether the 
expression of these molecules either in the maternal 
or foetal compartments is implicated in pregnancy 
malaria outcomes. 
 
3.4 Methods 
3.4.1 Mice and pregnancy monitoring 
Eight to twelve week-old C57BL/6(WT), C57BL/6.Tlr4
-/- 
(Tlr4
-/-
) and C57BL/6.Ifnar1
-/-
 (Ifnar1
-/-
) mice were 
obtained from the animal facility at Instituto 
Gulbenkian de Ciência. Mice were bred and maintained 
under specific pathogen free conditions. Isogenic 
matings were established as follows: WT, Tlr4
-/-
 or 
Ifnar1
-/- 
females were transferred to a cage with one 
isogenic male (two females: one male). For heterogenic 
matings, null mutant females were transferred to a 
cage either with wild-type or null mutant males (two 
females: one male). In the case of TLR4, an additional 
mating of null mutant females with heterozygous males 
was set. In all mating combinations, females were 
removed after 48 hours, being this considered 
gestational day 1 (G1). Pregnancy was monitored every 
other day by weighing females. Successful gestation 
was confirmed at G13 when females had an increase of 3 
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to 4 g in body weight. Abrupt weight loss after G13 
was an indicator of unsuccessful pregnancy. Animal 
housing and all procedures were in accordance with 
national regulations on animal experimentation and 
welfare and approved by the national animal welfare 
authorities. 
3.4.2 Parasites and infection 
In this study we used a parasite line originally 
derived from the P. berghei isolate NK65 at New York 
University, kindly provided by Dr Maria Mota 
(Instituto de Medicina Molecular, Lisbon, Portugal). 
Frozen IE stocks were expanded in C57BL/6 mice prior 
to infection. Infections in Figure 1 were performed by 
intra-peritoneal (i.p.) injection of 10
6
 infected 
erythrocytes (IE). For other experiments, pregnant 
mice and respective non-pregnant female controls were 
intravenously (i.v.) injected with 10
6
 infected 
erythrocytes. Parasitaemia was measured by flow 
cytometry [42] to detect infected erythrocytes stained 
with DRAQ5 (Biostatus Limited). The labeling of 
infected red blood cells with DRAQ5 is an adaptation 
of the manufacturer’s protocol for cell cycle analysis 
by flow cytometry. Briefly, a drop of blood was 
collected by tail pinching of infected mice into 400 
μl of FACS Buffer (PBS 1x, 2% FBS, sodium azide 
0.02%). DRAQ5 was added directly to the collected 
samples at a final concentration of 1μM. Samples were 
mixed by vortex to allow appropriate incorporation of 
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DRAQ5 into the parasite DNA and were immediately 
analyzed. Parasitaemia was expressed as the percent of 
stained cells within the erythrocyte morphological 
gate. Time of infection and amount of parasite are in 
accordance to the previously characterized model of 
PAM in C57BL/6 females infected with P. berghei NK65 
parasite [43]. 
3.4.3 Pregnancy outcome and foetal 
survival 
Infected pregnant mice were killed by CO2 narcosis and 
subjected to caesarian section on G18 and foetal 
weight and viability were evaluated. Foetuses were 
extracted from their amniotic envelop and viability 
was immediately evaluated by reactive movement to 
touching with pliers. The lack of prompt movement 
indicated that the foetus had recently died. 
Resorptions were identified as small implants with no 
discernible foetus and placenta. Non-viable foetuses 
(dead foetuses plus reabsorptions) and foetuses that 
have been expelled before the gestational day of 
analysis were recorded as stillbirths. Viable foetuses 
were killed combining hypothermia and CO2 narcosis. 
Weight of viable foetuses was recorded. 
3.4.4 Placenta preparations 
Placentas from infected and non-infected females 
sacrificed on the same gestational day separated in 
145 
 
two halves: one half was fixed in 10% formalin for 
further histological processing and the other half 
collected in lysis buffer (RNeasy Mini Kit - Qiagen) 
1% β-mercaptoethanol for RNA extraction. Paraffin-
embedded non-consecutive placenta sections were 
stained with hematoxylin-eosin (HE). 
3.4.5 Isolation of mouse trophoblast 
Isogenic matings were established as previously 
described with the only difference being that females 
were removed after 24 hours. At G18 females were 
killed by CO2 narcosis and subjected to caesarian 
section. Placentas were collected with careful peeling 
off the decidual tissue. Dissected placentas were kept 
in a Petri dish containing ice-cold washing buffer 
(Medum 199 1x – Sigma Aldrich # M9163-500ML, Glutamax 
- Gibco #35050-038 with a final L-glutamin 
concentration of 0.1g/L, Sodium Bicarbonate at 0.35g/L 
– Gibco #25080060 and Hepes Buffer at 20mM – Gibco 
#15630-056). Trophoblasts were isolated using an 
adaptation of a previously described protocol[44]. 
Placentas were sliced into small pieces with a sterile 
razor blade and collected into a 50 ml conical tube 
containing an equal volume of 2x concentrated 
digestion buffer (Colagenase, Sigma Aldrich #C9263-1G 
at 2mg/ml and DNAse Sigma Aldrich #DN25 at 40mg/ml). 
Digestion was performed in a water bath at 37ºC for 60 
minutes with vigorous pipetting every 10 minutes. 
Undigested material was removed, by passing the 
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digestion suspension through a 100µm (BD Falcon # 
#352360) cell strainer followed by a new passage 
through a 70µm cell strainer (BD Falcon # #352350) and 
centrifugation at 500g for 5 minutes at 4ºC. The 
resulting pellet was suspended in 10ml washing 
solution and centrifuged at 500g for 5 min at 4ºC. The 
pellet was suspended in 2ml wash solution and gently 
overlaid on a Percol® cushion (9.6ml Percol – Sigma 
Aldrich # P1644-1L, 13.4ml wash solution and 1.1ml 10x 
Medium 199) in a 50ml tube and centifuge at 30.000g 
for 30 minutes at 4ºC. The trophoblast layer [44] was 
collected, suspended in RPMI (Gibco #61870-044) 
complete (10% FBS – PAA # A15-152, 1% HEPES Buffer, 1% 
Sodium Pyruvate - Gibco® #11360-039, 0.1% 2-
Mercaptoethanol – Gibco® #31350-010, 1% 
Penincilin/Steptomicin - Gibco® #15140-122 and 0.1% 
Gentamicin – Sigma Aldrich #G1397-10ml) and 
centrifuged for 5 minutes at 500g at 4ºC . Isolated 
trophoblasts were suspended in RPMI complete and 
counted.  
3.4.6 Parasite synchronization 
Infected erythrocytes cells were obtained from 
infected non-pregnant mice with 10–20% parasitemia. In 
order to obtain mature blood stage parasite forms 
(trophozoites/ schizonts), P. berghei NK65 infected 
erythrocytes were synchronized as described elsewhere 
[45]. Mature forms enrichment yielded over 90% of 
infected cells. The enriched infected erythrocytes 
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preparations were suspended in RPMI complete at the 
desired concentration for posterior stimulation of 
isolated trophoblasts. 
3.4.7 Trophoblasts primary cultures 
Isolated trophoblasts from WT or Tlr4
-/-
 placentas were 
plated in 200µl of RPMI complete at the density of 
1x10
6 
cells/well in a 96 wells flat bottom plate. Cells 
were left in culture for 11 days at 37ºC 5% CO2. At 
day 11 the medium was replaced by either RPMI complete 
only, non-infected or P. berghei NK65 synchronized IE 
at the concentration of 1x10
6
 cells/ml, or purified LPS 
(Sigma Aldrich #L6511) at the final concentration of 
10µg/ml. At 4 and 18 hours after stimulation, cells 
were washed twice in RPMI complete and harvested by 
scraping for further analysis to measure RNA 
expression and to quantify uptake of P.berghei 
parasite by qReal Time PCR.  
3.4.8 RNA isolation and gene expression 
analysis 
Total RNA from individual placentas and isolated 
trophoblasts was obtained using an RNeasy Mini Kit 
(Qiagen), following the manufacturer’s instructions. 
Equal amounts of each RNA sample were converted to 
cDNA (Transcriptor First Strand cDNA Synthesis Kit, 
Roche). Tlr4, Tnfα, Ifnγ, Il-10, C3, C5a, Md-2 and 
CD68 expression was quantified using TaqMan Gene 
148 
 
Expression Assays from ABI (Mm00445273_m1, 
Mm00443258_m1, Mm01168134_m1, Mm00439614_m1, 
Mm00437838_m1, Mm00439275_m1, Mm01227593_m1 and 
Mm03047340_m1, respectively). For P. berghei 
quantification, used 18SRNA Taqman assays with 
specific primers: Forward 5’-CCG ATA ACG AAC GAG ATC 
TTA ACC T–3’, Reverse 5’- CGT CAA AAC CAA TCT CCC AAT 
AAA GG-3’ and Probe 5’– ACT CGC CGC TAA TTA G -3’ 
(FAM/MGB). The endogenous control Gapdh (Mouse GAPD 
Endogenous Control, ABI # 4352339E) was used in 
multiplex PCR assays with target genes. PCR reactions 
were performed with ABI Prism 7900HT system. ΔCt was 
calculated by subtracting the cycle threshold (Ct) of 
the target gene from Gapdh ΔCt. Gene expression 
results are plotted as fold change over WT non-
infected controls (ΔΔCt). 
3.4.9 Foetus genotyping 
Tlr4
-/-
 and Tlr4
+/-
 foetuses were distinguished by tail 
DNA genotyping. Foetal tails were cut and lysed 
overnight at 55ºC in lysis buffer (100mM Tris HCL pH 
8, 5Mm EDTA, 0.2% SDS and 200mM NaCl) with 1% 
Proteinase K. Genomic DNA was extracted with 2-
Propanol and used for TLR4 gene PCR with the following 
primers: 5’ CGT GTA AAC CAG CCA GGT TTT GAA GGC 3’ and 
5’ TGT TGC CCT TCA GTC ACA GAC ACT CTG 3’. PCR 
products were analyzed in agarose electrophoresis to 
distinguish mutant and WT alleles. Resorptions tissue 
was also collected for DNA preparation and genotyping. 
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3.4.10 Statistical analysis 
Survival curves were compared using the Log-Rank test 
(Mantel-Cox). Non-parametric Mann-Whitney test was 
applied in pair-wise comparisons of parasitaemia 
course and Figures 7A and 8B. Kruskal-Wallis non-
parametric test with Dunn’s multiple comparison test 
was used for comparisons in peripheral parasitaemia, 
placental parasite load and foetal wieght. Comparisons 
of abnormal stillbirth incidence were analyzed with χ
2
 
Fisher’s exact test. Data is considered significant 
when p<0.05. Data regarding parasitaemia in non-
pregnant females (Figure 1) and gene expression levels 
(Figure 7) is presented as mean values +/- standard 
error of the mean (SEM). 
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3.5 Results 
3.5.1 IFNAR1 but not TLR4 contribute to 
increased maternal peripheral 
parasitaemia 
The P. berghei NK65 parasite has been previously shown 
to induce death by hyperparasitaemia and pregnancy 
impairment in C57BL/6 mice [43]. In order to access 
Figure 1. Susceptibility to P. berghei NK65 infection in Tlr4
-/-
 and Ifnar1
-/- 
females. (A) Time-course parasitaemia and (B) survival of WT, Tlr4
-/-
 and  
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Ifnar1
-/-
 non-pregnant females infected with 10
6
 IE i.p. Parasitaemia was analized 
by FACS using DRAQ-5 labeled blood samples, at the indicated time points. 
Genotype pair-wise parasitaemia comparisons used Mann-Whitney test: wild-
type vs Tlr4
-/-
 (*p<0.05 **p<0.01); wild-type vs Ifnar1
-/-
 (
#
p<0.05) and Tlr4
-/-
 vs 
Ifnar1
-/- 
(
§
p<0.05). Survival curves were compared using the Log-Rank (Mantel-
Cox) test (p>0.05, n.s.).  
whether the absence of TLR4 or IFNAR1 would influence 
disease outcome in C57BL/6 (wild-type), Tlr4
-/- 
and 
Ifnar1
-/-
 nuliparous females, mice were infected with 
P. berghei NK65 and peripheral parasitaemia and 
survival were followed over time. The course of 
infection showed similar parasitaemia profile in the 
initial infection stages but absence of IFNAR1 or TLR4 
slightly anticipated rampant parasitaemia by day 16 
post-infection (Figure 1A). No differences were 
observed in survival rates with most females dying 
between days 22 and 32 independently of the genotype 
(Figure 1B). As no detectable differences were 
observed in initial parasite expansion and infection 
outcome, this experimental system provided a basis to 
evaluate the effect of pregnancy in the course of 
infection in Tlr4
-/-
 and Ifnar1
-/-
 females. This was not 
the case in Rag
-/-
, Cd8a
-/-
 and Tcrβ
-/- 
females 
(Supplementary Figure 1A and B) that showed marked 
differences in infection kinetics as compared to WT 
mice hampering the evaluation of pregnancy effects in 
these adaptive immune system impairments. The 
pregnancy status has been associated to increased 
susceptibility to Plasmodium infection as assessed by 
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higher levels of peripheral parasitaemia [46-49]. We 
followed peripheral parasitaemia in Tlr4
-/-
 and Ifnar1
-
/-
 pregnant females infected at G13. All pregnant 
females presented significantly higher peripheral 
parasitaemia levels as compared to the respective non-
pregnant controls (Figure 2). The absence of Tlr4 in 
both maternal and foetal compartments or in the 
maternal compartment alone did not significantly 
influenced peripheral parasitaemia in pregnant females 
when compared to WT (Figure 2A). Interestingly, Ifnar1
-
/-
 pregnant females showed significantly lower levels 
of peripheral IE when comparing to pregnant wild-type 
controls (Figure 2C). Furthermore, parasite expansion 
was also reduced in heterogenic pregnancies where 
Ifnar1
-/- 
pregnant females carry Ifnar1
+/-
 fetuses. These 
results suggest that during pregnancy absence of 
maternal IFNAR1 confers relative resistance to 
hyperparasitaemia development. 
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Figure 2. IFNAR1 but not TLR4 contribute to increased maternal peripheral 
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parasitaemia. Time course parasitaemia of P. berghei NK65 in pregnant (A and 
C) and non-pregnant (B and D) females for the indicated Tlr4 (A and B) and 
Ifnar1 (C and D) maternal/foetal genotype combinations. Animals were infected 
i.v. with 10
6
 IE at G13 for pregnant or day 0 for non-pregnants. Peripheral blood 
parasitaemia was followed by FACS in DRAQ-5 labelled samples. Kruskal-
Wallis with Dunn’s multiple comparison test: (A, B and D) p>0.05, n.s.; (C) 
*p<0.05; ** p<0.01. 
 
3.5.2 TLR4 and IFNAR1 influence foetal 
weight and stillbirth incidence in 
pregnancy associated malaria 
Experimental PAM is characterized by poor pregnancy 
outcomes that include low foetal weight and increased 
stillbirth incidence. The impact of TLR4 and INFAR1 in 
the pregnancy outcome was ascertained by comparing 
foetal weight at G18 and stillbirth frequency in 
infected and non-infected pregnant females of 
different maternal/foetal genotype combinations. The 
foetal weight loss induced by infection was less 
striking in the Tlr4
-/-
 pregnant females as compared to 
WT mice (Figure 3 A). Foetal weight was slightly 
recovered in Tlr4
-/-
 pregnant females that carried 
foetuses expressing TLR4. Nevertheless, no significant 
difference was found between the two conditions where 
the mother lacks TLR4 indicating that foetal TLR4 does 
not play a significant role in foetal weight loss 
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(Figure 3A). Likewise, analysis of Ifnar1 
maternal/foetal genotype combinations revealed that 
independently of foetal genotype, absence of maternal 
IFNAR1 resulted in significant reduction of foetal 
weight loss upon infection (Figure 3B).   
Interestingly, stillbirths induced by infection were 
significantly reduced in absence of TLR4. Incidence of 
abnormal stillbirth was 67% among wild-type infected females 
against 5% in Tlr4-/- mothers that carried Tlr4
+/-
 foetuses. 
This dramatic reduction in stillbirth occurrence 
almost reach stillbirth incidence in non-infected 
controls. Nevertheless, this result is not fully 
attributable to absence of maternal TLR4 as Tlr4
-/-
 
isogenic pregnancies showed 35% of abnormal stillbirth 
incidence. This result indicated that the isolated 
effect of TLR4 in the foetal compartment confers 
protection against abnormal stillbirth occurrence 
(Figure 4A). On the other hand, the effect of IFNAR1 
in stillbirth incidence was milder and the protective 
effect appears to be mainly due to the absence of 
IFNAR1 in the maternal compartment (Figure 4B). 
Together, these results suggest that maternal IFNAR1 
has a role in promoting parasite expansion in pregnant 
females and contributes to poor pregnancy outcomes. In 
contrast, TLR4 does not impact on parasitaemia 
development but expression of foetal TLR4 remarkably 
contributes to protect foetal viability in context of 
placental malaria. 
156 
 
Figure 3. TLR4 and IFNAR1 contribute to low foetal weight in pregnancy 
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associated malaria. Pregnant females were infected i.v. at G13 with 10
6
 IE. 
Viable foetuses weight was accessed in utero at G18 and shown for Tlr4 (A) or 
Ifnar1 (B) in the indicated maternal/foetal genotype combinations. Kruskal-
Wallis with Dunn’s multiple comparison test (A) infected vs infected **p<0.01, 
non-infected vs infected 
##
p<0.01, 
###
p<0.001 and non-infected vs non-infected 
p>0.05 n.s.; (B) *p<0.05, **p<0.01. 
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Figure 4. Maternal and foetal contributions of TLR4 or IFNAR1 to 
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abnormal stillbirth incidence in pregnancy associated malaria. Pregnant 
females were infected i.v. on G13 with 10
6
 IE. Abnormal stillbirth incidence was 
accessed at G18 and shown for Tlr4 (A) or Ifnar1 (B) in the indicated 
maternal/foetal genotype combinations. Stillbirth percent in individual females 
was calculated as the number of stillbirths /number of total foetuses X 100. Cut-
off for abnormal stillbirth incidence was established considering the maximum 
number of stillbirths in non-infected pregnant mice (dashed line). χ
2
 Fisher’s 
exact test *p<0.05, ***p<0.01. 
 
3.5.3 Placental parasite burden is 
differentially controlled by 
maternal and foetal IFNAR1 
Pathological features typical of PM include 
syncytiotrophoblast thickening, tissue destruction, 
fibrin deposits, thrombi formation and reduction of 
maternal blood space [10, 38, 39, 43, 50]. Although 
wild-type placenta appear to present more intense 
thickening and tissue disorganization (Figure 5C and 
D), overall sample analysis did not reveal any 
morphological differences attributable to specific 
Tlr4 or Ifnar1 genotypes (Figure 5C to L). This 
suggests that the observed differences in parasitaemia 
and in foetal impairments due to IFNAR1 or TLR4 did 
not correlate with microscopic alterations in placenta 
pathology. Likewise, no differences in placental 
parasite burden were detected in the different 
maternal/foetal Tlr4 genotype combinations 
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Figure 5. Placental histology of labyrinth zone. Representative 
photomicrographs of H&E stained placental sections of non-infected (A and B) 
and infected WT females (C and D), Tlr4
-/-
 placenta from Tlr4
-/-
 females (E and 
F), Tlr4
+/-
 placenta from Tlr4
-/-
 females (G and H), Ifnar1
-/-
 placenta from Ifnar1
-/- 
females (I and J) and Ifnar1
+/- 
 placenta from Ifnar1
-/- 
 females (K and L). Females 
were infected i.v. with 10
6
 P. berghei NK65 IE at G13 and placentas were 
collected on G18. Magnifications: 20x (A,C,E,G,I and K); 40x (B,D,F,H,J and L). 
A C E 
B D F 
G I K 
H J L 
A C E 
B D F 
G I K 
H J L 
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Figure 6. Differential control of placental parasite burden by maternal and 
foetal IFNAR1. Placentas were collected at G18 and RNA expression of P. 
berghei was evaluated by qReal Time PCR. ΔCT was calculated by subtracting 
the cycle threshold (Ct) of the target gene from the GAPDH. Kruskal-Wallis with 
Dunn´s multiple comparison test: (A) p>0.05, n.s.; (B) **p<0.01; ***p<0.001. 
(Figure 6A). At contrast, Ifnar1 genotypic 
combinations At contrast, Ifnar1 genotypic 
combinations revealed that both absence of maternal 
IFNAR1 and presence of foetal IFNAR1 have a role in 
reducing placental parasite burden (Figure 6B). These 
results indicate that maternal and foetal IFNAR1 have 
opposing effects in placental parasite burden. 
Interestingly, the observed foetal viability 
protection conferred by foetal TLR4 expression does 
not correlate with decreased placental parasite 
burden, suggesting that protection of fetal viability 
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by TLR4 was not dependent on controlling intra-
placental parasite accumulation. 
 
3.5.4 Tlr4 and Tnfα are downregulated in 
infected placentas 
The indication that foetal TLR4 plays a relevant role 
in foetal viability upon Plasmodium infection, lead us 
to analyze the molecular inflammatory profile in 
infected placentas. We found that Trl4 expression was 
downregulated in the infected placenta (Figure 7A). On 
the other hand, no evidence was found for involvement 
of pro-inflammatory molecules such as Ifnγ, Il-10, C3 
and C5a in placental infection (data not shown). 
Unexpectedly, we found that TNFα, expression in 
infected placentas was significantly decreased 
regardless the Tlr4 genotype (Figure 7B). This 
analysis suggests that similarly to placenta pathology 
the inflammatory response in the placenta was not 
prominently influenced by the Tlr4 maternal or foetal 
genoytpes. 
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Figure 7. Down-regulation of Tlr4 and Tnfα in infected placentas. Placentas 
were collected at G18 and RNA expression of Tlr4 (A) and Tnfα (B) were 
evaluated by qReal Time PCR. Results are plotted as fold change over WT non-
infected controls. Represented is the mean +/- SEM. Mann-Whitney test in (A) 
and Kruskal-Wallis with Dunn’s multiple comparison test (B) *p<0.05; 
**p<0.01; ***p<0.001 compares each mating genetic combination to non-
infected WT pregnant females. 
 
3.5.5 Foetal outcome and placenta 
parasitaemia in heterogenic 
siblings 
To ascertain whether protection of foetal viability 
afforded by foetal TLR4 was independent of maternal 
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factors we crossed Tlr4
-/-
 females with Tlr4
+/-
 males. 
This heterogenic pregnancies allowed us to compare 
Tlr4
-/-
 and Tlr4
+/-
 foetuses and their placentas in 
single Tlr4
-/-
 infected females. In accordance with 
previous observations in Tlr4 syngeneic foetus 
siblings (Figure 3A and 6A), we observed no 
significant differences in either foetal weight or 
parasite burden between Tlr4 heterogenic siblings 
(Figure 8A and B). We then evaluated stillbirth 
incidence in the progeny of three females in a total 
of 17 fetuses. Stillbirth incidence amongst foetuses 
with Tlr4
-/-
 genotype was 75% while Tlr4
+/-
 foetuses 
showed 20% stilbirths (Table 1). Although this result 
was borderline statistical significance (p=0.06) 
possibly due to small sample size, there was a clear 
trend towards a local foetal viability protective 
effect conferred by foetal TLR4 in absence of maternal 
TLR4. 
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Figure 8. Foetal Tlr4 genotype, foetal weight and placental parasite burden. 
Tlr4
-/-
 females were mated with Tlr4
+/-
 males resulting in pregnant females 
carrying both Tlr4
-/-
 and Tlr4
+/-
 fetuses. Pregnant females were infected i.v. on 
G13 with 10
6
 IE. Foetal weight was accessed at G18 (A) and parasite burden was 
quantified by qReal Time PCR (B). ΔCT was calculated by subtracting the cycle 
threshold (Ct) of the target gene from the GAPDH. Kruskal-Wallis with Dunn’s 
multiple comparison test in (A) infected vs non-infected (p>0.05 n.s.) and Mann-
Whitney test in (B) Tlr4
-/- 
vs Tlr4
+/-
 (p>0.05 n.s.). 
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Table 1. Differential viability of Tlr4
-/-
 and Tlr4
+/-
 sibling fetuses from three 
Tlr4
-/-
 pregnant females crossed with WT males. 
Foetal genotype Tlr4
-/-
 Tlr4
+/-
 
Mother f1 f2 f3 total f1 f2 f3 total 
Number of 
stillbirths 
4 1 4 9 1 0 0 1 
Number of 
viable foetuses 
1 1 1 3 1 1 2 4 
Stillbirth 
incidence % 
80% 50% 80% 75% 50% 0% 0% 20% 
χ
2 
comparison between total stillbirths and viable fetuses between Tlr4
-/-
 and 
Tlr4
+/-
 fetuses * p<0.05. 
 
3.5.6 TLR4 controls response of isolated 
trohphoblasts to IE 
Trophoblasts are the main cell type of foetal origin 
that contacts IE in the placental labyrinth. The 
indication that foetal TLR4 contributes to foetal 
viability in the infected placenta led us to 
investigate the role of TLR4 in the placental 
trophoblasts responses to IE. We isolated wild-type 
and Tlr4
-/-
 trophoblasts from non-infected term 
placentas and analyzed in vitro responses to exposure 
to P. berghei NK65 IE. As for total placenta, no 
detectable mRNA expression levels were found for pro-
inflammatory mediators such as Ifnγ, Il-10, and C5a 
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(not shown). Likewise, no differences were detected in 
the levels of Tnfα mRNA in Tlr4
-/-
 versus WT isolated 
trophoblasts. Nevertheless, at 4h post IE contact, a 
significant increase of Tnfα mRNA was detected 
indicating a pro-inflammatory response to parasitized 
erythrocytes (Figure 9A). The Tnfα mRNA falls to 
levels similar to non-stimulated trophoblasts at 18h 
post IE contact possibly explaining the observed in 
vivo absence of elevated Tnfα levels at G18, 5 days 
post-infection. 
Strikingly, we found that the amount of parasite 
uptake by Tlr4
-/-
 trophoblasts at 4h post IE contact 
was 3 fold lower as compared to WT trophoblasts 
suggesting that enhanced IE phagocytosis was mediated 
by TLR4 expression in trophoblasts. Interestingly, the 
amount of intra-trophoblast parasite after 18h of IE 
contact was reduced and indistinguishable in Tlr4
-/-
 
and WT trophoblasts. These results suggest that TLR4 
expression in trophoblasts contributes to uptake of IE 
but is not impacting the trophoblast production of 
pro-inflammatory cytokines upon contact with IE. 
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Figure 9. Tlr4 expression in purified trophoblasts increases P. berghei uptake 
but does not impact Tnfα upregulation. Trophoblasts were purified from G18 
non-infected placentas. Purified trophoblasts were either left with no stimulus or 
stimulated with non-infected or P. berghei infected erythrocytes and collected 
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after 4 or 18 hours. Levels of P. berghei RNA (A) and Tnfα mRNA expression 
(B) were evaluated by qReal Time PCR. Results are plotted as fold change over 
4h WT exposure to IE (A) or 4h no-stimulus WT trophoblasts (B). Representative 
results from 2 independent experiments are shown.  Fold increase is referred to 
4h post IE exposure in wild-type trophoblsat (A) or with no stimulus (B). 
 
Together the results suggest that trophoblast TLR4 is 
involved in parasite clearance in the placenta and 
that the mechanism of foetal viability protection 
mediated by foetal TLR4 is not related to impairments 
in the trophoblast pro-inflammatory response. 
 
3.6 Discussion 
We have analyzed the role of TLR4 and INFAR1 in 
experimental pregnancy-associated malaria with a focus 
on dissecting contributions of the maternal and foetal 
compartments to pregnancy outcome and placenta 
pathology. To this end we compared wild-type, isogenic 
and heterogenic null-mutation pregnancies in which 
mother and fetuses carry different genotypes in regard 
to the gene of interest. This allowed us to analyze 
the isolated effects of the gene of interest in the 
foetal compartment in the absence of the same gene in 
the maternal compartment.  
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In an experimental system that used the C57BL/6 mouse 
genetic background and P. berghei NK65 infection at 
mid-gestation, our results provided evidence for a 
dual role of TLR4 in PAM depending on whether it is 
expressed in the maternal compartment or in foetal 
placental tissues. Tlr4
-/-
 pregnant females 
susceptibility to PAM was indistinguishable from WT 
mice when evaluating maternal disease severity as 
revealed by increased levels of peripheral 
parasitaemia. Placental pathology was also prominent 
regarding placental parasite burden, trophoblast 
thickening and intravascular space disorganization. 
Nevertheless, PAM in heterogenic pregnancies was less 
deleterious to the foetus reducing both weight loss 
and stillbirth incidence. This suggests that maternal 
TLR4 plays a pathogenic role in the poor pregnancy 
outcomes observed in PAM. This observation is in line 
with the reports on bacterial infections showing that 
the maternal immune system severely impairs pregnancy 
outcome in a TLR4 dependent manner [22-24]. 
Unexpectedly, foetal TLR4 revealed to contribute to 
protect foetal viability. This indicated that while 
maternal TLR4 increased stillbirth incidence foetal 
TLR4 was promoting foetal survival. This effect was 
only detected when pregnant females lack Tlr4 
suggesting that maternal TLR4 pathogenic effects 
override foetal TLR4 protection. Analysis of Tlr4
-/-
 
mothers carrying heterogenic siblings (either Tlr4
-/-
 
or Tlr4
+/-
) confirmed that in the same infection 
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environment foetal TLR4 did not impact on placental 
parasite but decreased the occurrence of stillbirths. 
This finding corroborates the notion that the 
expression of TLR4 in foetal tissue has an active role 
in protecting foetal viability in presence of IE. 
Interestingly, we found that P. berghei infection 
induced a significant reduction in Tlr4 mRNA levels 
(Figure 7A) as opposed to reports of placental TLR4 
up-regulation in course of bacterial infection [22]. 
Furthermore, the amount of parasite uptake in Tlr4
-/-
 
trophoblast cultures was strikingly lower as compared 
to WT trophoblasts. This indicated that TLR4 
expression in trophoblasts contributes to parasite 
clearance but is downregulated during infection, 
suggesting that the parasite counteracts this 
placental host response. Infection-induced 
downregulation of TLR4 may in part explain the finding 
that “in vitro” production of pro-inflammatory 
mediators is not altered in absence of TLR4 expression 
in trophoblasts. 
Although several reports claim that TNFα expression is 
upregulated upon Plasmodium infection [8, 9, 51], 
there is still controversy to whether this is a 
hallmark of PAM. In fact, studies have reported low 
plasma levels of TNF with no differences between 
aborting and non-aborting females [52]. Our data 
suggest that the TNFα response in the placenta could 
be transient and not related to pregnancy outcome. We 
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concluded that trophoblast pro-inflammatory responses 
do not provide an explanatory mechanism for the 
improved foetal viability observed in Tlr4
+/-
 foetuses. 
Our findings raise the possibility that Tlr4 signaling 
takes part of a trophoblast response to IE that favors 
foetal viability through a non-inflammation dependent 
mechanism. 
The joint effect of maternal and foetal TLR4 suggests 
that whenever maternal TLR4 is present, pregnancy 
outcome will be jeopardized and the foetal TLR4 
protection is override. It should be noted that 
identification of feotal viability protection by 
foetal TLR4, relies on observations made in hemizygous 
Tlr4 expression (Tlr4
+/-
 mice and placentas) where TLR4 
expression is conferred only by the paternal allele. 
Therefore, it is conceivable that homozygous 
expression of foetal Tlr4 in absence of maternal TLR4 
would lead to stronger foetal protection phenotypes. 
Contrary to TLR4, a significant increase in peripheral 
and placental parasite burden is attributable to 
maternal IFNAR1. This increase in parasite burden 
correlated with foetal weight loss and increased 
stillbirth incidence in WT mice as compared to 
heterogenic pregnancies. This suggests that maternal 
IFNAR1 contributes to poor foetal outcome in PAM 
through increasing parasite burden. In opposition, 
foetal IFNAR1 showed to confer resistance to parasite 
accumulation in the placenta but does not 
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significantly influence foetal development and 
survival. This suggested that reduction of parasite 
burden in the placenta is not enough to ameliorate PAM 
outcomes. 
Our findings on the involvement of TLR4 and IFNAR1 in 
PAM highlight that expression of these innate immunity 
mediators in the maternal compartment has a 
deleterious role in PAM outcome. Nevertheless, 
maternal IFNAR1 appears to promote parasite expansion 
while maternal TLR4 does not impact on parasite burden 
but possibly impacts on maternal pro-inflammatory 
response. On the other hand, TLR4 and IFNAR1 foetal 
counterparts mediate protective responses in the 
placenta of distinct nature. Foetal IFNAR1 confers 
relative resistance to placental parasite expansion or 
accumulation possibly trough enhancing anti-parasite 
responses but has no effect on poor fetal outcomes. In 
contrast, foetal TLR4 protects foetal viability but 
does not influence placenta parasite burden. 
Together the data suggests that mechanisms of foetal 
viability protection mediated by foetal factors are 
dissociated from responses that control parasite 
burden in the placenta. Such mechanisms could be of 
crucial relevance to prevent abortion and stillbirth 
in PAM. These findings introduce the notion that, 
regardless of anti-parasite therapeutics, the severe 
consequences of PAM could be lessened if foetal 
protective mechanisms were pharmacologically enhanced. 
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3.8 Supplementary Figure  
Supplementary Figure 1. Susceptibility to infection of B6, Rag2
-/-
, Cd8a
-/- 
and 
Tcrβ
-/- 
females. (A) Time-course parasitaemia and (B) survival of P. berghei 
NK65 infected WT, Rag2
-/-
, Cd8a
-/-
 and Tcrβ
-/-
 non-pregnant females. Animals 
were infected i.p. with 10
6
 IE. Parasitaemia of DRAQ-5 labelled samples was 
followed by FACS. (A) Parasitaemia in the different time points was compared 
using Mann-Whitney test: WT vs Rag2-/- (*p<0.05 **p<0.01); WT vs Cd8a-/- 
(
#
p<0.05) and WT vs Tcrβ
-/-
 (p>0.05, n.s.). (B) Survival curves were compared 
using the Log-Rank (Mantel-Cox) test: WT vs Rag2
-/-
 (***p<0.005); WT vs 
Cd8a
-/-
 (
##
p<0.01) and WT vs Tcrβ
-/-
 (
§§§
p<0.005). 
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“The past five years have seen an impressive increase in international 
funding for malaria prevention, control and elimination. Following the 
call in 2008 by United Nations Secretary-General, Ban Ki-moon for 
universal access to malaria interventions, we saw a rapid expansion in the 
distribution of life-saving commodities in sub-Saharan Africa, the 
continent with the highest burden of malaria. The concerted effort by 
endemic country governments, donors and global malaria partners has led 
to strengthened disease control and visible results on the ground. During 
the past decade, an estimated 1.1 million malaria deaths were averted, 
primarily as a result of a scale-up of malaria interventions.” 
Nevertheless, “Behind the statistics and graphs lies a great and 
needless tragedy: malaria - an entirely preventable and treatable disease - 
still takes the life of an African child every minute. The most vulnerable 
communities in the world continue to lack sufficient access to long-lasting 
insecticidal nets, indoor residual spraying, diagnostic testing, and 
artemisinin-based combination therapies. Unfortunately, only modest 
increases in access to these interventions were observed between 2010 and 
2011 – the first such plateauing in the past 5 years. It is imperative that we 
act now to ensure that the recent momentum, and its results, are not 
diminished.”(Quotations from World Malaria Report 2012 
[1]) 
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Despite the efforts and clear improvements in malaria 
elimination, much is yet to be done in order to 
achieve full disease control and prevent the millions 
of deaths still registered every year in endemic 
regions. 
Development of an effective vaccine has been one of 
the main goals of the scientific community and 
considered the best cost-effective strategy to achieve 
full protection. Nonetheless, so far, just one vaccine 
has entered the phase 3 trials with only moderate 
efficacy in reducing severe malaria episodes in 
infants [2-4]. 
Unfortunately, the high degree of Plasmodium genetic 
variability and plasticity poses an exceedingly 
challenge in the development of a highly effective 
malaria vaccine. In the context of PAM, the VAR2CSA 
protein appears as the ideal vaccine candidate. Not 
only it is expressed on the surface of placenta 
adhering IEs, as VAR2CSA specific antibodies are 
prominently acquired by pregnant women and correlate 
with protection against PAM. Nevertheless, major 
challenges have been delaying the development of a 
VAR2CSA vaccine as this is a large and polymorphic 
protein. The DBL2X N-terminal part of VAR2CSA contains 
the binding site to placental CSA and is thus 
currently recognized as the preferential region for 
vaccine development [5]. Nonetheless, the 
identification of small epitopes able to induce 
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adhesion inhibitory antibody responses continues a 
major challenge for vaccine development [6, 7].  
In other perspective, Plasmodium infection has also 
put a strong evolutionary selective force in the human 
genome. Various genetic host traits, with a direct 
influence in the severity of infection and disease 
outcome, are already well documented. Amongst these, 
the protection afforded by the hereditary red blood 
cell (RBC) traits as the sickle cell trait [8, 9], 
Glucose-6-phosphate dehydrogenase deficiency [10] and 
α and β-talassemia [11]. These RBC genetic traits have 
all arisen in malaria endemic areas, and their high 
level of prevalence is thought to result from the 
significant degrees of protection they confer against 
Plasmodium infection. 
In addition to this intense selective pressure with 
RBC as the prime target for evolutionary adaptation, 
genetic polymorphisms related to immunity have also 
been identified. 
CXCL10 [12], TLR4 [13], IL-10 and IL-17 [14], ICAM-1 
[15], IFNAR-1 [16, 17], TGFB2 [18], IFNGR1 [19], 
CD40L, IL-1A and IL-13 [20], TNF-α [21] and IL-8 [22, 
23] have been shown or strongly suggested to be 
associated with Plasmodium infection manifestations. 
In this context, a growing understanding of the 
molecular basis of host-parasite interactions and 
genetic factors conferring resistance to the disease 
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would provide invaluable information on the molecular 
basis of protective immunity. This type of analysis 
might soon prove to be the most promising approach in 
the development of new therapies – such as an 
effective vaccine - to definitely improve Plasmodium 
infection outcome.  
Also during PAM, genetic polymorphism such as KLRK1 
and IL-7/IL-7R [24], genes related to the complement 
system [25], TLR-1 [26], FUT9 [27], TLR-4 and TLR-9 
[28] and the TNF2 variant [29] have been indicated to 
be involved in disease. Nevertheless, despite some 
genetic polymorphisms have been suggested to be 
involved in PAM, the genetic analysis of this form of 
the disease has been neglected when comparing to the 
amount of data available to other severe forms as is 
the case of CM.  
Interestingly, amongst polymorphisms involved in PM, 
FLT1 has been demonstrated to have not only a role due 
to the maternal genetic variant but, also the infant 
genotype is under selective pressure during infection 
and influences pregnancy outcome in a parity dependent 
manner [30]. 
Taking into account these interesting observations 
and, intending to further identify genetic factors 
involved in Pregnancy Associated Malaria, we have 
decided to dissect maternal from foetal molecular 
contribution to disease outcome. 
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While there is growing body of evidence for human 
genetic factors controlling the outcome of malaria 
infection, their molecular basis is still poorly 
understood owing to the ethic and operational 
limitations. In this context, murine models appear as 
an excellent alternative genetic tool with comparative 
mapping studies showing similar genetic-controlled 
mechanisms of resistance [31]. 
Although there is a significant offer of murine PAM 
models, at the beginning of this thesis, none of these 
models allowed the study of gestation outcome in the 
C57BL/6 genetic background. Being the goal of this 
work the study of genetic and molecular basis of PAM 
and end gestation outcome, I needed to gain access to 
the multitude of KO strains available in this murine 
background. In this regard, three new PAM models were 
established [32] using three P. berghei lines that do 
not induce cerebral malaria in this background. This 
analysis provides evidence that parasite factors 
determining cerebral malaria are not required to the 
development of placental infection and PAM pathology. 
Interestingly, the heterogeneity in pathology and 
pregnancy outcome observed with the different 
Plasmodium lines used reflects the wide range of 
clinical manifestations observed in women that have 
malaria during pregnancy including increased levels of 
parasitaemia [33-36], increased number of abortions, 
preterm delivery, intrauterine growth retardation, low 
birth weight, maternal mortality [37-41] and 
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structural placenta alterations such as trophoblast 
layer thickening and consequent vascular space 
reduction [42, 43]. Interestingly, parasite burden in 
the placenta was not a major determinant of PM 
severity as the distinct pathology patterns observed 
between infections with NK65, K173 and ANKAΔpm4 did 
not correlate with differences in placenta parasite 
accumulation. As such, with this work I have developed 
new PAM models where the different P. berghei lines 
represent a fine-tuning resource in constructing 
experimental systems to study different aspects of 
pregnancy associated malaria pathogenesis.  
Having established these new experimental models, the 
next step was to (1) discriminate effects exerted by 
foetal and maternal-derived inflammatory factors in 
PAM pathogenesis and (2) to ascertain whether innate 
immune responses play a role as mechanisms of 
effective foetal protection in PAM. 
To this end, I have analyzed the role of TLR4 and 
INFAR1 in experimental pregnancy-associated malaria 
with a focus on pregnancy outcome and placenta 
pathology. These molecules were chosen due to previous 
reports showing their involvement either in poor 
pregnancy outcomes and/or malaria severity. 
Considering the new PAM models established, NK65 
infection was chosen for this part of the work as it 
induced the most severe syndrome comprising 
significantly lower foetal weight and decreased 
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placental vascular area, higher percentage of 
nonviable foetuses per mother and lower number of live 
newborns. In addition, NK65 was the only parasite line 
causing maternal death before delivery. 
Focusing on dissecting maternal and foetal TLR4 or 
IFNAR1 contributions to PAM outcome, wild-type, 
isogenic and heterogenic null-mutation pregnancies in 
which mother and fetuses carry different genotypes in 
regard to the gene of interest were compared. This new 
approach allowed, for the first time, to analyze the 
isolated effects of the gene of interest in the foetal 
and maternal compartments.  
With this experimental setup I have provided evidence 
for a dual role of TLR4 in PAM depending on whether it 
is expressed in the maternal compartment or in foetal 
placental tissues. While Tlr4
-/-
 pregnant females 
presented peripheral parasite levels indistinguishable 
from wild-type, PAM in heterogenic pregnancies was 
less deleterious to the foetus reducing both weight 
loss and stillbirth incidence. This suggests that 
maternal TLR4 plays a pathogenic role in the poor 
pregnancy outcomes observed in PAM. Unexpectedly, 
foetal TLR4 revealed to contribute to protect foetal 
viability. Nevertheless, this effect was only detected 
when pregnant females lack TLR4 suggesting that 
maternal TLR4 pathogenic effects override foetal TLR4 
protection. The protective role of foetal TLR4 was 
further confirmed in Tlr4
-/-
 mothers carrying 
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heterogenic siblings (either Tlr4
-/-
 or Tlr4
+/-
) where 
foetal TLR4 decreased the occurrence of stillbirths 
confirming that the expression of TLR4 in foetal 
tissue has an active role in protecting foetal 
viability in presence of IE. 
Interestingly, we found that P. berghei infection 
induced a significant reduction in Tlr4 mRNA levels 
and, the amount of parasite uptake in Tlr4
-/-
 
trophoblast cultures was strikingly lower as compared 
to wild-type trophoblasts. Additionally, the 
expression of TLR4 in trophoblasts does not seem to 
intervene in production of pro-inflammatory mediators 
such as TNFα, upon contact with IE.  
Together, these data raise the possibility that Tlr4 
signaling takes part of a trophoblast response to IE 
that favors foetal viability through a mechanism that 
do not impact the prominent pro-inflammatory response. 
Contrary to Tlr4, a significant increase in peripheral 
and placental parasite burden is attributable to 
maternal Ifnar1, correlating with increased foetal 
weight loss and stillbirths, independently of foetal 
genotype. On the other hand, foetal IFNAR1 showed to 
confer resistance to parasite accumulation in the 
placenta but, contrary to foetal TLR4, does not 
significantly influence foetal development and 
survival. This suggested that reduction of parasite 
burden in the placenta is not enough to ameliorate PAM 
outcomes. 
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Overall, this work challenges the commonly accepted 
pathogenesis model linking placental parasite burden, 
placental pathology and pregnancy outcome. By showing 
that the pathogenesis model intervenients can be 
uncoupled, the current notion that PAM clinical 
outcomes are determined by placental parasite burden 
is put into question. 
To date, much effort has been put towards the 
understanding of the maternal immune response during 
pregnancy. It is well accepted that important 
immunological changes occur during the gestation 
period which can influence various diseases outcome.  
Nonetheless, there is a growing concern that the 
maternal immune system is not walking alone on this 
specific temporal immunological niche [44]. The active 
role trophoblasts and placental macrophages have 
during pregnancy is becoming increasingly evident and 
should definitely not be ignored. 
In this work it is presented strong evidence that 
foetal tissue can significantly interfere in foetal 
outcome upon malaria infection.  
Furthermore, it is shown that mechanisms of foetal 
viability protection mediated by foetal factors can be 
dissociated from the mechanistic action of the same 
molecule in the maternal compartment. Such mechanisms 
could be of crucial relevance to prevent abortion and 
stillbirth in PAM.  
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This work raises the important fact that, regardless 
of anti-parasite therapeutics, the severe consequences 
of PAM could be lessened if foetal protective 
mechanisms were pharmacologically enhanced. 
In this sense, if robust therapies are to be applied 
in preventing poor foetal outcome during PAM, studies 
where maternal and foetal molecular mechanisms are 
dissected should be an essential part on the 
scientific community contribution to disease 
understanding. Furthermore, our results highlight the 
relevance of including in epidemiological studies not 
only maternal genetic analysis but also foetal genetic 
screening as it might help revealing patterns of 
genetically-determined clinical outcomes of malaria 
during pregnancy.  
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